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Summary 
Controlled release systems have become an innovative technique to treat diseases like 
cancer by the targeted delivery to individual cells and tissues. There is an urgent need to 
achieve efficacious and safe delivery with minimal nonspecific uptake by healthy tissues. 
Among the polymer-based nanoparticulate systems for drug delivery, nanoparticles (NPs) 
have represented a promising opportunity as delivery system due to their degradation in 
water-soluble compounds that enter the normal metabolic pathways of the organism and 
their capacity to modify pharmacokinetics and the drug tissue distribution profile. 
 
An engineered and versatile targeted nano-platform for the delivery of paclitaxel (PTX) 
across the blood brain barrier (BBB) with the aim to improve its therapeutic effect on 
human glioma cells has been developed. A novel biodegradable polymer has been 
synthetized and custom tailored NPs have been obtained. The method allows to modify 
the targeted drug delivery for efficiently transport and release of active drug molecule 
across the BBB. Aiming a dual-targeting strategy, functionalization with ligands known to 
be efficiently transported across BBB by a membrane receptor that also is over-expressed 
on human glioma cells has been employed to shuttle PTX from blood to brain and then 
target glioma cells. In vivo properties of the NPs have been explored to assess their 
biological profile and since the pressing need for careful evaluation, new strategies for NPs 
radiolabeling with the aim to investigate their in vivo fate, specifically stability in biological 
environments (stealthiness), biodistribution and pharmacokinetic, have been adopted.  
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Resumen 
Los sistemas de liberación controlada de medicamentos, mediante la administración 
dirigida individualmente a células y tejidos, se han convertido en una técnica innovadora 
para tratar enfermedades como el cáncer. Existe una necesidad urgente para lograr una 
liberación eficaz y segura que incluya una mínima absorción no específica para los tejidos 
sanos. Entre los sistemas nanopartículados a base de polímeros para la administración de 
fármacos, las nanopartículas (NPs) han representado una oportunidad prometedora como 
sistema de suministro. Entre sus ventajas se puede destacar su perfil de degradación en 
compuestos hidrosolubles y no tóxicos, que se eliminan siguiendo las vías metabólicas 
normales del organismo. Por otro lado, presentan una elevada capacidad de modificar la 
farmacocinética y el perfil de distribución del medicamento en los tejidos.  
En esta tesis se ha desarrollado una nano-plataforma específica y versátil para la 
liberación de paclitaxel (PTX) a través de la barrera hematoencefálica (BHE)  con el 
objetivo de mejorar su efecto terapéutico sobre las células de glioma humano.  
Se ha sintetizado un nuevo polímero biodegradable gracias al cual se han obtenido NPs 
personalizadas a medida. El método permite modificar el tipo administración dirigida de 
los fármacos para conseguir un transporte y una liberación de las moléculas de principio 
activo eficiente y segura. Se ha desarrollado el objetivo de seguir una estrategia de 
selección dual que consiste en transportar el PTX desde la sangre hasta el cerebro y luego 
dirigirse a las células de glioma. Para ello se ha empleado la funcionalización con 
marcadores capaces de atravesar eficientemente la BHE a través de un receptor de 
membrana que también está sobre-expresado en las células de glioma humano. Para 
evaluar el perfil biológico de las NPs se han explorado sus propiedades in vivo y dada la 
urgente necesidad de una evaluación fiable, se han adoptado nuevas estrategias para 
radiomarcar NPs con el objetivo de investigar su destino in vivo, la estabilidad en entornos 
biológicos, la biodistribución y la farmacocinética. 
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1.1 Introduction 
In the recent years, significant advances in the field of nanotechnology, especially in 
material science and medicine, have been achieved. In particular, the medical application 
of nanotechnologies, usually termed nanomedicine 1–5 has given a decisive impulse to the 
development of various types of drug-loaded nanocarriers, usually ranging from 
1 to 1000 nm. An extensive variety of nanocarriers or nanoparticulate systems, composed 
of different materials including lipids, polymers and inorganic materials have been 
proposed in the biomedical field, resulting in delivery systems that depending on their 
physiochemical properties will be suitable for different applications (Scheme 1.1). In drug 
delivery technologies, nanocarriers are designed (i) to protect a drug from in vivo 
degradation; (ii) to enhance drug absorption by facilitating diffusion through epithelium; 
(iii) to modify pharmacokinetics and drug tissue distribution profile; (iv) to improve 
intracellular penetration and subcellular distribution. Furthermore, surface modification 
of pharmaceutical nanocarriers is normally used to control their biological fate in a 
desirable way. The most important results of such modification include an increased 
stability and half-life of nanocarriers in the circulation, passive or active targeting into the 
required pathological zone and responsiveness to local stimuli such as pathology-
associated changes in local pH and/or temperature.  
 
Scheme 1.1 Lipid and polymer-based nanoparticulate systems used in the field of drug delivery and active 
targeting 6 
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The wide application of biodegradable polymers in this field is due to their degradation by 
chemical or enzymatic processes in water-soluble low molecular weight compounds that 
enter the normal metabolic pathways of the organism. The most used polymer-based 
nanoparticulate systems for drug delivery are nanoparticles (NPs), vesicles, polymeric 
micelles and nanoconjugates. (Scheme 1.2).   
Micelles are self-assembling nanosized colloidal particles which form spontaneoulsy under 
certain concentrations and temperatures from amphiphilic or surface-active molecules, 
which consist of two clearly distinct regions with opposite affinities towards a given 
solvent. Hydrophobic segments of amphiphilic molecules form the core of a micelle, while 
hydrophilic fragments form the micelle shell. When used as drug carriers in aqueous 
media, micelles solubilize poorly soluble and non-polar molecules within the micelle core.7  
Polymersomes are polymer-based vesicular shells that are formed upon hydratation of 
amphiphilic block copolymers. As the nanocapsules, polymersomes are indeed vesicular 
systems in which the drug is confined to a reservoir or within a cavity surrounded by a 
polymer coating.  Accurate selection of polymer M, hydrophilic/hydrophobic ratio and 
chemistry impart polymersomes with a broad and tunable range of carrier properties. 
These systems are capable of encapsulating a large range of therapeutically water soluble 
active molecules and biomolecules.8  
Polymer–drug conjugates are macromolecular system where a prodrugs is covalently 
bound to a water soluble polymeric carrier, normally via a biodegradable linker. 
Amphiphilic polymer-drug conjugates in aqueous solution can form micelles or micelle-like 
nanoassemblies in which the lipophilic drug is confined in the internal core of the system.9 
Finally, Nanoparticles are solid colloidal systems in which the drug is physically dispersed, 
dissolved, or chemically bounded to the polymer chains.10 Depending on the method 
employed for their preparation, nanospheres or nanocapsules can be obtained. 
Nanospheres are matrix-like systems in which the drug can be either entrapped inside the 
NPs or adsorbed on their surface. On the contrary, nanocapsules are vesicular systems 
Chapter I – Introduction 
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which are formed by a drug-containing liquid core, composed of oil or water depending on 
the encapsulated compound and surrounded by a single polymeric membrane11.  
Both types of NPs can be prepared from a variety of materials such as proteins, 
polysaccharides and synthetic biodegradable polymers, depending on many factors such 
as i) size of the desired NPs, ii) properties of the drug to be encapsulated (aqueous 
solubility, stability, etc.), iii) surface characteristics and functionality, iv) degree of 
biodegradability and biocompatibility, and v) drug release profile of the final product.  
The methods to prepare NPs can be divided into two main categories depending on if the 
formulation requires a polymerization reaction or is obtained by preformed prepolymers. 
In the last year, due to the Food and Drug Administration (FDA) approval for human use, 
there has been a significant interest in employing synthetic polymers like 
poly(ethyleneglycol) (PEG) 12, polylactide (PLA)13, and poly(D,L-lactide–co-glycolide)14 
(PLGA).  
 
Scheme 1.2 Polymeric nanoplatforms for drug delivery15 
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Many of the described polymer-based nanoparticulate systems developed for solid tumor 
treatment, have proved to be efficacious cancer therapeutics16. Cancer in its myriad forms 
affects millions of people worldwide and is growing at an alarming rate to become the 
world’s deadliest disease of all times.17 With more than ten million people diagnosed 
annually, cancer is a major cause of mortality. It is known that cancer develops via a 
multistep carcinogenesis process involving numerous cellular physiological systems such 
as cell signaling and apoptosis, making it a highly complex disease.18  
Treatment of brain cancer remains one of the biggest challenges in oncology. Anaplastic 
astrocytomas and glioblastoma multiforme (GBM) are the most aggressive brain tumors 
with median survival of patients of 24 and 9 months, respectively.19 Moreover GBM is the 
most frequent primary central nervous system tumor, and represents the second cause of 
cancer death in adults less than 35 years of age.20 Because of its aggressiveness, due to 
rapid proliferation, high angiogenic level and tendency to infiltrate the surrounding 
healthy tissues, it is impossible to make the complete removal of the tumor by surgical 
methods. Despite many advances in conventional treatment such as chemotherapy, 
surgery and radiation, cancer therapy is still far from optimal because it is plagued by 
some drawbacks.  Challenges encountered by current cancer therapies are non-specific 
systemic distribution of antitumor agents, inadequate drug concentrations in the tumor 
site, limited ability to monitor therapeutic responses and development of MDR. The 
therapeutic effects of present chemotherapy for GMB treatments are very limited mainly 
because of the presence of the blood-brain barrier (BBB) that separates the blood from 
the cerebral parenchyma and functions as a tremendously effective barrier for the 
delivery of potential neurotherapeutics into the brain parenchyma.21,22 Virtually, all large 
molecule drugs, more than 98% of small molecule candidate drugs and the majority of 
novel protein and peptide are unable to reach the brain tissue due to their poor 
permeability across the BBB.  
The BBB is formed by brain endothelial cells that line the cerebral microvessels. It is 
supported by other cell types surrounding the endothelium, such as astrocytes and 
Chapter I – Introduction 
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pericytes (Figure 1.1).23 These surrounding cells contribute to the induction of many 
barrier characteristics of the endothelium, such as tight junctions (Figure 1.1), which 
closely join the endothelial cells together. Next to being a “physical barrier”, the BBB is 
also a “transport barrier”, since it contains numerous transporter proteins and 
transcytosis mechanisms that mediate the uptake and efflux of molecules. Third, a 
“metabolic barrier” is formed by the expression of metabolizing enzymes such as 
peptidases, cytochrome P450 enzymes and monoamine oxidases.24 All of these barrier 
functions control and regulate both inward and outward transfer of molecules between 
blood and the brain.  
 
 
Figure 1.1 Neurovascular unit. (A) a modified merged confocal image of an arteriole consisting of endothelial 
and smooth muscle, surrounded by astrocytic processes (red) and some of the neuronal processes (green); 
(B) a segment of arteriolar endothelium shows tight junctions (arrowheads) along the interendothelial 
space25 
 
There are several routes for the transport of molecules across the BBB (Scheme 1.3). 
Paracellular transport of hydrophilic molecules is highly restricted by the tight junctions 
between brain endothelial cells.  Lipid-soluble molecules with relatively small molecular 
weight (<400 Da), adequate lipophilicity, neutral or uncharged nature, low hydrogen 
bonding potential and sufficiently high unbound plasma fraction  are able to achieve 
passive transcellular lipophilic diffusion across endothelial cells of the BBB. For a variety of 
molecules that are essential for brain function, such as amino acids, glucose, peptides, and 
A B 
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proteins, specific endogenous BBB transporters exist. These are expressed at both the 
luminal and the basolateral membranes of the endothelium.24 These transporters can be 
either defined as carriers or receptors. Carriers are membrane-restricted systems which 
are generally responsible for the transport of small molecules with a fixed size and mass 
smaller than 600 Da. Carrier-mediated transcytosis is used for the delivery of nutrients 
such as glucose, amino acids, and purine bases to the brain. This type of transport is 
substrate-selective, and only drugs that closely mimic the endogenous carrier substrates 
will be taken up.26 On the other hand, receptor-mediated endocytosis is initiated by the 
binding of a receptor-specific ligand. Following binding, the substance is internalized and 
transported via the early endosome to the lysosome, or transcytosed to the plasma 
membrane.26 The only way for larger molecules and particles such as antibodies, 
lipoproteins, proteins and NPs to be transported into the brain is via receptor mediated 
endocytosis.27 Finally, endocytosis at the BBB can occur also through adsorption binding. 
Adsorptive-mediated endocytosis is initiated by the binding of polycationic substances to 
negative charges on the endothelial plasma membrane and the substance is internalized 
and transported. Next to these influx systems, many efflux mechanisms exist at the BBB, 
including P-glycoprotein, multidrug resistance (MDR)-related protein, ABC transporters, 
and several others.28 They restrict entry of drugs virtually able to access the brain by 
promoting luminal release of compounds and are important in removing harmful 
substances from the brain. Substrates for efflux transporters include peptides, lipids, 
cholesterol, hormones, CNS drugs and metabolites.29  
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Scheme 1.3 Transport mechanism at the BBB  site for shuttling of endogenous and/or exogenous 
substrates 30 
 
The use of the receptor-mediated transport, highly expressed on the BBB luminal side, 
have become an attractive strategy for drug design in attempt to shuttle drug molecules 
across the BBB. It is reported that various receptors are present on the luminal endothelial 
plasma membranes, including the transferrin receptor, the insulin receptor, endothelial 
grow factors receptor, and low-density lipoprotein receptor-related protein (LRP).31 LRP, a 
member of the low-density lipoprotein receptor family (LDLR), is highly expressed on BBB 
32 and mediate the transcytosis of multiple ligands across the BBB such as lactoferrin 33 
and melanotransferrin. Moreover, LRP is also over-expressed on human glioma cells 34, 
making LRP a potential targeted receptor for brain tumor drug delivery systems, with 
dual-targeting capability for both BBB and glioma cells. 
 
Although many advances in conventional treatments for cancer therapy, to make further 
progress it is necessary to put emphasis on other existing, but still under appreciated, 
therapeutic approaches. An increased interest is being focused on nanotechnological 
approaches in cancer treatment based on the concept that the therapeutic effects of 
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many anticancer drugs could be significantly improved if delivery of the drug occurred 
specifically to tumors, achieving a reduction of toxic side effects.35 The key point to 
develop targeted drug delivery systems able to selectively recognize specific cells or 
tissues, can be found in the words of Paul Ehrlich, Nobel Prize for Medicine in 1908, who 
suggested the concept of “magic bullet”: a drug that selectively destroys diseased cells but 
is not harmful to healthy cells.36 
There has been intense interest in identifying polymeric NPs that are best suited for 
oncology applications. Nanoparticles carriers are capable of addressing several drug 
delivery problems, which could not be effectively solved in the past and include 
overcoming MDR phenomenon and penetrating cellular barriers that may limit drug 
accessibility to intended targets. Pharmacokinetics of the NPs is crucial and depends on 
several physiochemical characteristics of the carrier such as size, surface charge, shape, 
nature and density of coating, composition, stability, steric stabilization, dose and route of 
administration.37,38  
Further advantages of NPs result from the ability to incorporate hydrophobic drugs at 
concentrations greater than their intrinsic water solubility39, the possibilities to greatly 
modify their composition, their circulation time, the drug release profile and the target 
ability.40 Nevertheless, multiple obstacles must be overcome in order to have an effective 
injectable drug delivery system.41 The major challenges include overcoming clearance in 
the body and increasing the uptake into target tissue/cells. Natural elimination processes 
include both renal clearance and uptake by the Mononuclear Phagocyte System (MPS). 
Renal clearance of intravascular agents is a process involving glomerular filtration, tubular 
secretion and finally elimination of the molecule through urinary excretion. Filtration of 
particles through the glomerular capillary wall is highly dependent on molecule size and is 
referred to as the filtration-size threshold. Molecules with a diameter of less than 6 nm 
are typically filtered, while those bigger than 8 nm are not typically capable of undergo 
glomerular filtration.42 MPS uptake proceeds quickly and must be avoided in order to have 
an acceptable circulation time for nanocarriers. The MPS, also referred to as the 
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reticuloendothelial system (RES), is the main natural clearance system for particles not 
filtered by the kidneys acting via phagocytosis. Recognition by the MPS is aided by 
opsonization, which consists in the binding of blood opsonins to nanocarriers’ surface thus 
inducing its phagocytosis and accumulation in the liver (Kuppfer cells). The liver acts as a 
reservoir toward nanocarriers conditioning their rapid first-phase disappearance from the 
blood and, in case of biodegradable systems, their second-phase escape from the body 
under degraded and excretable form. In order to overcome the opsonization of 
nanocarriers, a number of widely used and effective methods have been investigated to 
make nanocarriers “invisible” to the immune system, creating long-circulating NPs, known 
also as stealth NPs. Interestingly, by coating the NPs surface with hydrophilic polymers, 
such as PEG, poloxamers, or hydrophilic polysaccharides, it is possible to create a hydrated 
water barrier that prevents the interaction with blood components and therefore the 
attack of phagocytes.43,44 Furthermore, a steric stabilization limits also aggregation 
between particles themselves in the blood and contribute to system stability in biological 
environments. Stealth NPs exhibit decreased levels of uptake by the MPS and, 
consequently, a prolonged circulation time in the blood, and are able to accumulate in 
solid tumors passing through their leaky vasculature (passive targeting). Indeed, all 
nanoparticles in general benefit from enhanced permeation and retention (EPR) that 
allows for passive tumor targeting.45,46 The EPR effect (Scheme 1.4) describes the 
accumulation of NPs in tumor tissues, due to fenestrations in the blood vessel’s 
endothelial layer and a significantly reduced lymphatic drainage in the tumor tissue.47 
Therefore, passive targeting mediated by the EPR effect is the most common mechanism 
used for the uptake of NPs or polymers at oncological target sites.48,49 This explains why 
the PEGylation strategy appears to be a key nanotechnological advance, allowing 
PEGylated nanocarriers to exhibit a prolonged circulation time, thus leading to an 
increased opportunity to reach its site of action. Gref et al 50 were the first to report the 
advantages of PEGylation on PLGA-PEG NPs, resulting in a substantial increase in blood 
residence time. The chain length, shape, and density of PEG on the particle surface have 
been shown to be the main parameters affecting NPs surface hydrophilicity and 
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phagocytosis. Most research indicates that a PEG chain with molecular weight of 1500 Da 
or greater is required to achieve increased MPS-escape. This minimum MW is most likely 
due to the loss in flexibility of shorter PEG chains. Also, it has been shown that as 
molecular weight is increased, the blood circulation half-life of the PEGylated particles is 
also increased, which may be due in part to the increased chain flexibility of higher MW 
PEG polymers. In addition to chain molecular weight, surface chain density and 
conformation are also critical factors to achieve improved stealth characteristics, although 
these two aspects are much more interrelated.51 A high surface coverage ensures that the 
entire surface of NP is covered but also decreases the mobility of the PEG chains and thus 
decreases the steric hindrance properties of the PEG layer. 
 On the basis of this scenario, the vast majority of nanomedicines developed for drug 
targeting to tumors rely on the EPR effect. These primarily include long-circulating 
liposomes, polymers and micelles. Examples of passively targeted nanomedicines 
approved for clinical use are Myocet®, Doxil®, Daunoxome®, Abraxane® and Genexol-
PM®. Several additional passively tumor-targeted nanomedicines are currently in clinical 
trials, and a large number of other ones are in early- and late-stage of preclinical 
development. 
 
Scheme 1.4 Enhanced Permeation and Retention (EPR) effect of macromolecular structures as drug delivery 
systems in malignant tissue. 52 
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Nevertheless, the EPR effect is not suited for all tumors because the degree of tumor 
vascularization and porosity of tumor vessels can vary with the tumor type and status. 
Moreover, the occurrence of the so-called “accelerated blood clearance (ABC) 
phenomenon” produced by PEGylation, explains the urgent need for nanoparticulate 
systems able to serve as efficient therapeutic tools against disease.35,40,53 Engineered 
polymer-based colloids represent one of the most promising opportunities for treatment 
of many diseases. The possibility to load them with a drug and to functionalize them with 
targeting ligands, intended to be recognized by particular cells, paved the way to the so-
called active targeting 54–56. Ideally, for anticancer drugs to be effective in cancer 
treatment, they should first (after administration) be able to reach the desired tumor 
tissues through the penetration of barriers in the body with minimal loss of activity in the 
bloodstream. Second, after reaching the tumor tissue, drugs should be released from the 
carrier at optimal rate (e.g., 3-10% per day), because a too slow release results in 
insufficient concentrations at sites of action. Otherwise, a release that is too rapid would 
lead to a high concentration of free drug in circulation (no accumulation in the tumor), 
resulting in a considerably lower therapeutic effect and undesired systemic toxicity. A 
thorough careful engineering of polymeric NPs, including functionalization with targeting 
ligand, is needed to promote the cellular uptake through the binding of the NPs with the 
receptors expressed at the surface of cancer cells or blood vessels. A variety of ligands 
including folate, transferrin, antibodies, amino acids, peptides and protein can be 
conjugated to polymeric nanoparticles to target receptors commonly overexpressed on a 
number of cancer types57–59. Efficient binding and internalization requires that receptors 
are expressed exclusively on target sites relative to normal cells.  
 
At present, many delivery systems are under clinical trials but the actively targeted 
nanomedicines several times failed to demonstrate benefit at the preclinical level. It can 
likely be mostly attributed to the fact that there are quite a number of anatomical and 
physiological barriers that need to be overcome to finding the target cells. In this scenario, 
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new delivery systems need to be explored for the therapeutically active drug molecule to 
be able to reach the site of action, without affecting healthy organs and tissues 60. 
Developing novel tailored nanocarriers in terms of polymer and functionalization, which 
may influence the pharmacokinetic profile, biodistribution and antitumor activity of the 
resulting delivery system, demands to be examined. This is the motivation of the thesis. 
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1.2 Aims 
The main objective of this thesis is to develop multifunctional polymeric nanoparticles 
capable of efficient and brain targeted drug delivery. 
 
In particular, the goals of the present thesis can be summarized in the following points: 
 
 To develop and optimize a modified nanoprecipitation method in order to obtain 
customized NPs with increased drug loading and evaluate its release profile 
(Chapter II). 
 
  To achieve functionalized NPs for the potential use as drug delivery vectors for 
efficiently transport and release of PTX into the brain and evaluate their in vitro 
efficiency (Chapter III). 
 
 To explore the in vivo characteristics of the NPs and assess their biological profile 
in terms of physicochemical properties, pharmacokinetics and bio-distribution by 
means of novel radiolabeling strategies (Chapter IV). 
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1.3 Content of this Dissertation  
To overcome the limitations of the conventional drug delivery methods, an engineered 
and versatile targeted nano-platform is presented in this work. It consisted in designing 
and developing novel biodegradable polymeric NPs for the delivery of PTX across the BBB 
with the aim to improve its therapeutic effect on human glioma cells and minimize side 
effects. 
 
First, a novel biodegradable block co-polymer (P) is synthetized in order to be employed 
for developing a custom tailored polymeric drug delivery system. In this line, Chapter II 
exploits the obtained novel polymer to fabricate PTX loaded NPs and optimize a modified 
nanoprecipitation method, achieving a clear correlation between NPs characteristics and 
formulation parameters. It grants the possibility to obtain entirely customized NPs in 
terms of physiochemical properties such as size, zeta-potential, drug loading and release 
profile. 
 
Chapter III describes how obtained NPs can be converted into effective target drug 
delivery system for efficiently transport and release of active drug molecule. The 
developed strategy allows to select the target by functionalizing NPs with the appropriate 
family of peptides. The strategy assessed for coupling NPs and peptides is the crosslinking 
via sulfhydryl groups because the reaction is very selective and crosslinking at these sites 
does not significantly modify the peptide structure. This part of the thesis is focused in 
developing a nanoparticulate system for PTX release with dual-targeting capability. 
Functionalization was carried out employing a family of peptides known to be efficiently 
transported across BBB by a membrane receptor (LRP-1) that also is over-expressed on 
human glioma cells. In this work the dual-targeting effect, consisting of shuttle PTX from 
blood to brain and then target glioma cells, is optimized and the effectiveness of the 
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system is evaluated in vitro by cellular assays. In particular, to assess transendothelial 
transport of PTX, an in vitro BBB model is developed and a study on the internalization 
mechanism is carried out. Moreover, cellular uptake and the cytotoxic effect on glioma 
cells are also evaluated. 
 
The last part of this thesis is focused in the in vivo characterization of the developed 
nanocarriers. Relevant in vivo properties of the NPs are explored to assess their biological 
profile in view of their application as a target anticancer delivery system.  Although the 
current investigations on targeted polymeric nanoparticles are encouraging, there is a 
pressing need for careful evaluation in terms of physicochemical properties in vivo, 
pharmacokinetics and bio-distribution. Thus, Chapter IV explores new strategies for NPs 
radiolabeling with the aim to investigate their in vivo fate, focusing on stability in 
biological environments (stealthiness), biodistribution and brain uptake. Rate constants 
related to the influx of the radiolabeled NPs across BBB are also studied. This work was 
mainly performed in the Radiochemistry and Nuclear Imaging Laboratory at Centro de 
Investigación Cooperativa en Biomateriales (CIC biomaGUNE) in San Sebastian (Spain) in 
collaboration with Dr. Jordi LLop, group leader of molecular imaging and radiochemistry 
group.  
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2.1 Introduction 
According to the actual needs in tumor treatment, in this initial part of the thesis, a novel 
biodegradable block co-polymer (P) was synthetized to develop long circulating NPs for 
anticancer drug delivery. As it has been introduced in Chapter I, a wide variety of polymers 
offers the possibility to develop new nanoparticulate systems, mostly because of their 
flexibility, properties and biodegradation process. Synthetic polymers, especially linear 
polyesters such as poly (ε-caprolactone) (PCL), polylactide (PLA) and poly (lactide-co-
glycolide) (PLGA), have been widely utilized as the polymeric matrix materials of drug 
delivery systems 1–3. Many methods have been developed for preparing NPs; these 
methods can be divided into two main categories depending on if the formulation 
requires a polymerization reaction or is obtained by preformed polymer 4. The 
nanoprecipitation technique was first developed by Fessi and co-workers 5. This technique 
uses interfacial preformed polymer deposition followed by solvent displacement and the 
NPs formation is instantaneous and the entire procedure is carried out in only one step 
(Scheme 2.1) 6. In this work Paclitaxel loaded nanoparticles (PTX-NPs) were prepared by a 
modified nanoprecipitation method and emulsification-solvent evaporation method. 
 
 
 
 
Scheme 2.1 Preparation of polymeric nanocarriers by nanoprecipitation 7 
In the last years there has been an intensive research on the development of 
biodegradable nanoparticles (NPs) as a suitable means for controlled drug release and 
targeting 8. As discussed in Chapter I, the major goals in designing NPs as a delivery system 
are to control surface properties, particles size, drug loading and release of 
pharmacologically active agent1,9.  In this sense, a great deal of effort on customizing NPs 
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was put to find a precise correlation between NPs characteristics and different 
experimental parameters so as to obtain completely customized NPs in terms of size, zeta-
potential, drug content and release profile. Surface properties plays a key role on the 
therapeutic efficacy of NPs. To minimize the adsorption of opsonins and thereafter the 
clearance from the blood, stealthy or long-circulating NPs are achieved by introducing 
flexible hydrophilic coating (Figure 2.1) 10. Moghimi D. S. et al. have demonstrated that the 
effect of size on NPs biodistribution is non-linear and organ specific 11. This is due to 
physical and physiological barriers that systematically administered NPs encounter in 
organs 12. For a suitable in vivo biodistribution the size of NPs should typically be 
controlled at less than 200 nm with narrow polydispersities 13. For this reason, the work is 
carried out with the aim to obtain a very monodisperse NPs population in which NPs could 
be equipped with an optimal external hydrophilic coating (PEG-corona).  
 
Figure 2.1 Representations of PEG conformations, obtained through incorporation onto surfaces at different 
densities.(Left) Low surface coverage levels of PEG lead to the “mushroom” configuration and (Right) High 
surface coverage levels restrict the mobility of the PEG chains and lead to the “brush” configuration 14 
 
An important parameter for NPs intended to use in clinical is drug loading 15. High drug 
loaded polymeric nanosphere remains as an unmet need, indeed, at lower drug content, 
larger amounts of delivery vehicles need to be administered.  This chapter optimizes the 
encapsulation of PTX into NPs increasing considerably the payload and by differential 
scanning calorimetry assess if a physical state change of the drug occurs. To complete 
characterization of the developed NPs, an in vitro release profile of PTX was also carried 
out, with the aim to customize the system in order to achieve a slower and more 
controlled release for a prolonged period of time. To achieve effective drug delivery, a 
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controlled release profile is also important in order to reach site-specific action of the drug 
at therapeutically optimal rate and dosage regimen. PLA NPs, typically prepared via 
nanoprecipitation1 tend to give NPs with various formulation challenges that remain to be 
addressed. Moreover, PLA NPs typically show ‘‘burst’’ drug release profiles in aqueous 
solution, with 80–90% of the encapsulated drug rapidly released during the first few 
hours16.  
 
Biodegradable NPs have been used as sustained release vehicles for administering active 
agents such as natural or synthetic organic or inorganic entities, proteins, peptides and 
nucleic acids. The active agent is either dissolved, entrapped, encapsulated, or attached to 
the NPs matrix 17. 
 
 Among the encapsulated drugs, PTX, a semisynthetic taxane (Scheme 2.2), is a successful 
chemotherapeutic agents that has been approved to effectively kill a wide variety of solid 
tumors. The anticancer mechanism of PTX as a potent inhibitor of cancer cell replication is 
related to its ability to block cancer cells in the late G2-mitotic phase of the cell cycle by 
stimulating microtubule polymerization and suppressing their dynamics. In analogy to 
many other anticancer drugs, the difficulties in clinical applications of PTX are due to the 
poor water solubility. Commercial formulation of PTX for clinical treatment is constituted 
with ethanol and Cremophor EL, which has been associated with acute hypersensitivity 
reaction 18 and side effects including neutropenia, cardiac arrhythmias, dose-related 
myalgia, neuropathy and serious killing of normal cells 19. To achieve desired therapeutic 
performance of PTX, various formulations were proposed, among them liposomes, which 
can reduce the side effects but also have some disadvantages such as low entrapment 
efficiency 20.  As a result, this chapter seeks to solve some of these restrictions and achieve 
optimized NPs not only by tailoring their physicochemical properties but also by 
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evaluating their biocompatibility and anti-proliferative efficiency against glioblastoma cells 
lines. 
 
Scheme 2.2 Chemical structure of PTX 
2.2 Experimental Section  
2.2.1 Materials 
 
1.8-Octanediol (98%) and PEG (MW 1.5 KDa) were purchased from Sigma (USA). Glutaric 
acid (99%) was obtained from Alfa Aesar (USA). PTX (≥ 97%) was provided by Yunnan 
Hande Bio-Tech CO, LTD, P.R. China. FBS was purchased from Lonza, L-Glutamine and 
Penicillin/Streptomycin were provided by Labclinics. All other chemicals of analytical grade 
were purchased from Sigma (Sigma–Aldrich, Germany). 
2.2.2 Synthesis of Block Co-polymer (P) 
 
Block co-polymer (P) constituted by rigid and flexible alternating blocks was synthetized 
by the esterification of 1.8-Octanediol with glutaric acid and subsequently with PEG 1500. 
Glutaric acid (6 g, 45 mmol) and 1.8-Octanediol (5.53 g, 37 mmol) were reacted in a 
microwave reactor (Discovery CEM) at a power of 100 W for 1 hour. The reaction was 
performed under vacuum (100 mbar) with continuous stirring and cooling the system with 
compressed air to maintain the temperature constant at 120º C. Once the glutaric acid 
exceeding prepolymer or rigid block was generated, it was subsequently reacted with PEG 
1500 which is added in a 1:1 weight ratio with the prepolymer. The polymerization 
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reaction was performed in the microwave reactor with the conditions above described. 
The resulting block co-polymer (P) was dried at room temperature and used for NPs 
preparation without further treatment.  
2.2.3 Characterization of Block Co-Polymer (P) 
To determinate the molecular structure of block co-polymer P a Fourier Transform 
Infrared (FTIR) analysis was performed using a Thermo Scientific Nicolet iS10 
spectrophotometer. The composition of the P co-polymer was determined by proton 
nuclear magnetic resonance 1H-NMR in CDCl3 at 300 MHz (Varian 400 MR). The weight-
averaged molecular weight and molecular weight distribution of the obtained polymers 
were determined using a gel permeation chromatography (GPC) LaChrome Elite from 
Hitachi, with pump and refractive index (RI) detector from Hitachi. The following 
conditions were adopted: the column was Shodex KF-603, the mobile phase was THF HPLC 
grade, and flow rate was 0.5 ml/min. The samples were dissolved in THF, filtered, and 
then 20 µl were injected. The molecular weights of the copolymers were determined 
relative to the standards curve, prepared using a series of Shodex SM-105 polystyrene 
standards. 
2.2.4 Formulation of NPs 
 
Nanoprecipitation  
NPs were prepared according to a modified nanoprecipitation method (or solvent 
displacement method)5. 20 mg of P and a specified quantity of PTX were dissolved in 
acetone, a suitable organic solvent pharmacologically accepted with regard to toxicity, to 
form the diffusing phase. This phase was then added to dispersing phase in which the 
polymer is insoluble, by means of a syringe, controlled by a syringe-pump (KD scientific), 
positioned with the needle directly in the medium, under a magnetic stirring of 120 rpm 
and at room temperature. The resulting NPs suspension was allowed to stir uncovered at 
room temperature until complete evaporation of the organic solvent. Drug free NPs were 
prepared according to the same procedure. To investigate the influence of formulation 
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parameters on NPs formation, size and zeta potential the following variables were 
studied: 
 methanol, ethanol and water were used as dispersing phase (no-solvent) 
 for each no-solvent, the ratio S/NS was varied from 1:2 to 1:20 (v/v)     
 polymer concentration in the organic phase was increased from 10 to 50 mg/ml  
 a range of drug dissolved in the organic phase (theoretical drug loading) from 0% 
to 25% was used   
In each set of experiment only one formulation variable was changed at a time while the 
other parameters were kept constant. The NPs were processed as above in triplicate. NPs 
were purified by centrifugation (Hettich Centrifuge, EBA 21, 4000 g, 45 min.) with ultra-
centrifugal device (Amicon Ultra-15, Ultracel membrane with 100,000 MWCO, Millipore, 
USA). The supernatant containing the dissolved free drug was discarded and the pellet 
freeze-dried (Telstar, LyoAlfa 6) for 48 hours. Freeze-drying was carried out without 
lyoprotectant. The nanoparticle recovery was calculated using Equation 2.1 
NPs recovery (%) =
Mass of NPs recovered × 100
Mass of polymer and drug used in formulation
 
Equation 2.1 
 
 
Emulsion 
 
To demonstrate the capability of block co-polymer P to be employed as a drug delivery 
system, NPs were also prepared by a modified emulsification by sonication-solvent 
evaporation 21. This method involved the use of an organic phase consisting of polymer at 
10 mg/ml concentration and selected amounts of PTX, dissolved in 1 ml DCM. This organic 
phase was added to an aqueous phase to form an emulsion, which was broken down into 
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nanodroplets by applying external energy through a 10 seconds pulsing (2”on/2”off) 
sonication at 100% amplitude. Upon the solvent evaporated whit magnetic stirring at 300 
rpm and under atmospheric conditions for 4 hours, a colloidal suspension of PTX-NPs was 
obtained. NPs were purified as described above and freeze-dried with cryoprotectant to 
ensure optimal re-suspension. 
2.2.5 Characterization of NPs 
 
Determination of NPs Size and polydispersities 
The NPs size distributions and polydispersity were measured by Dynamic Light Scattering 
(DLS) (Malvern Zeta Sizer Nano Series) at 25ºC and at scattering angle of 90º using sample 
appropriately diluted with mQ water. For each sample the intensity-weighted mean value 
was recorded as the average of three measurements. The results were expressed as 
mean ± S.D for two replicate sample. Further measurements were performed by 
Nanoparticles Tracking Analysis (NTA) (Nanosight LM 10, Laser Module LM 14C), with a 
532 nm laser beam passed through a prism-edged optical flat and validating all data with 
video files of the NPs moving under Brownian motion to determinate NPs size distribution 
and monodispersity. 
Surface Charge and morphology 
NPs were also characterized with respect to zeta (ζ) potential, the analysis was performed 
in triplicate on Malvern ZetaSizer (Nano Series) with a Smoluchowsky constant F (Ka) of 1.5 
to achieve zeta potential values from electrophoretic mobility. For each sample the mean 
zeta potential was recorded as the average of three measurements. The results were 
expressed as mean ± S.D for two replicate sample. The size and morphology of the NPs 
were observed by Transmission Electron Microscopy (TEM) (Jeol Jem 2011). A drop of the 
NPs suspension (10 µl) was placed on carbon electron microscopy grids (Holey Carbon 
Film) and air-dried before analyze at an acceleration voltage of 200 kV without negative 
staining. 
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Thermal Characterization 
 
The physical state (crystalline versus amorphous) and miscibility of PTX in the NPs were 
characterized by Differential Scanning Calorimetry (DSC) (Mettler Toledo DSC821e) on the 
glass transition temperature (Tg) or melting point (Tm). As a control pure PTX, empty NPs 
and the physical mixture of PTX with empty NPs (1:1 w/w) was also analyzed. 
Approximately 4-5 mg of each sample, sealed in a standard aluminum pan, was purged 
with dry nitrogen at a flow rate of 50 ml/min while the sample was heated from 50ºC to 
300ºC at a rate of 10ºC/min. 
Drug Incorporation Efficiency 
Freeze-dried NPs loaded with PTX were dissolved in acetonitrile and the amount of 
entrapped drug was detected by Ultra Performance Liquid Chromatography (UPLC) 
(Waters ACQUITY UPLC H-Class). A reverse phase BEH C18 column (1.7 µm 2.1 x 50 mm) 
was used. The mobile phase consisted of a mixture of acetonitrile and water (60:40 v/v) 
and was delivered at a flow rate of 0.6 ml/min. PTX was quantified by UV detection (λ=227 
nm, Waters TUV detector). A calibration curve of standard PTX solution was used to 
obtain the PTX concentration, which was linear over the range of 60.5 – 0.47 µg/ml with a 
correlation coefficient of R2=0.9998. Drug incorporation efficiency was expressed as drug 
content (D.C. % w/w) and encapsulation efficiency (E.E. %); represented by Equation 2.2 
and Equation 2.3, respectively. For each sample the mean value was recorded as the 
average of three measurements. The results were expressed as mean ± S.D for two 
replicate. 
Drug Content (%
w
w
) =
Mass of drug in NPs × 100
Mass of NPs recovered
 
Equation 2.2 
Encapsulation Efficiency(%) =
Mass of drug in NPs × 100
Mass of drug used in formulation
 
Equation 2.3 
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In vitro Drug Release Analysis 
 
In vitro drug release from PTX loaded NPs was performed using a modified dialysis-bag 
diffusion technique, as reported by Kim et al. and Averineni et al. (22, 23). Specifically, a 
known amount of freeze-dried PTX-NPs, corresponding to 0.3 mg of PTX, was suspended 
in a dialysis bag (regenerated cellulose tubular membrane, Cellu SEP® T2, nominalMWCO 
6000– 8000, membrane filtration products, Inc, TX) containing 15 ml of release PBS 
solution (0.1 M at pH 7.4 and 0.3% v/v of Tween-80). The bag containing NPs suspension 
was placed in a 50 ml Eppendorf® Tube (Fisher Scientific Company, Houston, TX) 
containing 30ml of release medium (PBSsolution and 0.3% v/v of Tween-80). The whole 
system was then placed in an orbital shaking incubator (LM-450D, Yihder Co., Ltd) at 37°C 
and at shaking speed of 200 rpm. At pre-decided time points 1 ml aliquots of release 
medium was withdrawn and replaced with an equal volume of fresh medium to maintain 
the sink conditions. The withdrawn aliquots were filtered through a 0.2 μm syringe filter 
directly into UPLC vials and immediately capped. The amount of PTX released in each time 
interval was determined by UPLC with a reverse phase BEH C18 column (1.7 μm 2.1×50 
mm). The mobile phase consisted of a mixture of Acetonitrile/Ammonium Acetate Buffer 
(20 mM, pH 4.5) = 60/40 delivered at a flow rate of 0.6 ml/min. PTX was quantified by UV 
detection (λ=227 nm, Waters TUV detector); the reported values are averages ± S.D. of 
three replicates. The percent drug release was calculated as percentage of the total 
encapsulated drug. For the polymer degradation studies an UPLC (Waters ACQUITY UPLC 
H-Class) equipped with a TOFMS detector was used, using the same UPLC conditions 
above described. 
2.2.6 Cell experiment 
 
In vitro immunological assay 
Hemocompatibility of PTX-NPs was evaluated diluting NPs in PBS (0.1 M pH 7.4) at 
concentrations of 10 and 100 µg/ml. Hemocompatibility test was carried out after blood 
exposure. Interaction of NPs with blood was analyzed using normal human plasma 
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collected under citrate 15 minutes before starting blood exposure during 15 minutes at 
37ºC and at atmospheric pressure. First analysis was the hemolysis test and according to 
Drabkin’s method, when free hemoglobin <2% NPs were considered non haemolyitic; 2-
5% slightly haemolytic and >5% haemolytic. Further experiments were blood cell counting 
and quantification of complement activation adopting the determination of the C3a 
concentration (ELISA kit). Finally, analysis of the activation of the coagulation either by the 
intrinsic (TCA test) or the extrinsic (Quick) pathways was performed. 
In vitro anti-proliferative efficiency 
In order to evaluate the cytotoxicity of the PTX-NPs on U-87 MG cells, the cells were 
grown in DMEM supplemented with 10% FBS, 1% L-Glutamine and 1% 
Penicillin/Streptomycin and plated in 96-well plates at a cellular density of 30.000cells/ml. 
After 24 h, medium was aspirated and substituted with 100 µl of various PTX 
concentration (10, 20 nM) of 3, 5 and 8% theoretical loaded PTX-NPs suspensions. Empty 
NPs were also examined with the concentration corresponding to that of 10 nM of PTX. 
One column, cells with PTX at 10 and 20 nM, was used as positive control; one column, 
cells without NPs, was used as the control; another column, without cells, was used as the 
blank. After 1, 4, 6, 8 and 11 days, cell viability was assessed via MTS (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, Promega Corporation, USA) following the 
manufacturer instructions. Briefly, cells were washed with PBS and incubated with a 
solution of the MTS reagent and complete media at 37ºC. The absorption (A), which 
represented cell viability was measured via a microplate reader (Spectramax M2e) at the 
wavelength of 490 nm. Cell viability was calculated by Equation 2.4 and the errors bar 
were obtained from triplicate samples. 
Cell viability (%) =
A𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑙𝑎𝑛𝑘 
A𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −  𝐴𝑏𝑙𝑎𝑛𝑘
× 100 
Equation 2.4  
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2.3 Results and Discussion 
2.3.1 Synthesis and Characterization of Block Co-polymer (P) 
Block co-polymer P constituted by flexible blocks (PEG 1500) and rigid blocks (1.8-
Octanediol and Glutaric Acid), was synthetized by polycondensation in a microwave 
reactor, under vacuum, at 120ºC and 100 W (Scheme 2.3). The identity and purity (with 
respect residual monomers) of the co-polymer P were determined by FTIR. Figure 2.2 
shows a representative FTIR spectrum of P, which is consistent with the structure of the 
expected polymer. It shows that the strong band at 1732 cm-1 is assigned to C=O stretch of 
the ester band. The absorption band at 3449 cm-1 is attributed to the terminal hydroxyl 
group and that at 1500-1045 cm-1 is due to the C–O stretching of the ester band. C-H 
stretch of CH2 is observed at absorption band 2919-2850 cm-1. The composition of P co-
polymer is confirmed by 1H-NMR (Figure 2.3). One of the prominent features is a large 
peak at 3.64 ppm (peak b), corresponding to the methylene groups of the PEG 1500. The 
multiplets at 4.06 and at 1.61 ppm (peak a and e) correspond to the CH2 protons of 1.8- 
octanediol. The multiplets at 2.37 and 1.94 ppm (peak c and d) are assigned to the glutaric 
acid methylene protons in α and β position relative to carbonyl group, respectively. The 
weight-averaged molecular weight and molecular weight distribution of the obtained 
prepolymer and P co-polymer were determined by means of GPC. The molecular weight 
were found to be 1069 and 2335 for the prepolymer and P co-polymer, respectively. The 
PDI was narrow, which was around 1.8 for the prepolymer and 2.01 for the P co-polymer.  
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Scheme 2.3 Synthesis of block-co polymer P by polycondensation 
 
 
Figure 2.2 FTIR spectra of the P co-polymer 
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Figure 2.3 1H-NMR spectra of P co-polymer in CDCl3 
2.3.2 Preparation and Characterization of NPs 
 
Effects of varying formulation parameters to control NPs size and zeta 
potential   
NPs with and without PTX loading and based on different formulation parameters were 
prepared by a modified nanoprecipitation method 5. An experimental design of NPs 
fabrication was selected to investigate how formulation variables (no-solvent type, 
solvent/no-solvent ratio and polymer concentration) could affect NPs characteristics. The 
experiments were designed with the ultimate goal of tailoring NPs in terms of size and 
zeta potential. As a starting point for controlling NPs characteristics, we first studied the 
effect of different no-solvent types used to disperse organic phase. Senichev et al. have 
demonstrated that a solvent/no-solvent (S/NS) system affects the diffusion rate and thus 
the NPs size 22. To analyze the impact of a S/NS system we studied the affinity of the 
solvent (acetone) for the no-solvent by means of the interaction parameter (χ). This 
interaction is expressed as: 
𝜒 =
𝑉𝑁𝑆
𝑅𝑇
(𝛿𝑆 − 𝛿𝑁𝑆)
2 
Equation 2.5 
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Where VNS is the molar volume of the non-solvent (here, methanol 40.7 cm3/mol, ethanol 
58.5 cm3/mol and water 18.016 cm3/mol) and δ is the Hildebrand solubility parameter. 
The calculated interaction parameters (Table 2.1) were then plotted against NPs size and 
presented in Figure 2.4. As expected, the higher the interaction parameter, the larger the 
NPs. We chose to investigate the relationship between NPs size and S/NS miscibility and 
observed a dependence of NPs size on the solubility parameter. As shown in Figure 2.5 an 
increase of S/NS miscibility (decrease in Δδ, as indicated by the arrow shown in Figure 2.5) 
led to a decrease in the mean NPs size, with all other formulations parameters held 
constant. 
 
Table 2.1 Non-solvent properties. Miscibility and calculated interaction parameters χ of solvent/non-solvent 
binary mixture 
Non-Solvent 
Solubility parameter, 
δ (MPa)1/2 
Δδ 
Interaction parameter 
a, b  χ 
Water 48 28.3 5.14 
Methanol 29.7 10 1.44 
Ethanol 26.2 6,5 0.87 
a Solvent: Acetone, b Calculated using equation Equation 2.5  and for T=25ºC (298 K). Polymer was not 
take into account 
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Figure 2.4 Relationship between calculated interaction parameter χ of binary S/NS mixture and NPs size (◊ 
Ethanol, ∆ Methanol, □ Water). NPs size determined by DLS 
 
Figure 2.5 Effect of varying formulation parameters on NPs size: modifying the non-solvent type and the 
acetone/non-solvent ration (1:2, 1:10, 1:20). NPs size determined by DLS; data represented mean ± SD (n=3) 
 
Concurrently with the investigation of the effect of S/NS, we studied the effect of altering 
the S/NS ratio during nanoprecipitation. When the ratio of diffusion of the acetone into 
the non-solvent was varied for a fixed polymer concentration (Figure 2.5), a correlation of 
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NPs size with S/NS ratio was observed. This correlation was remarked for all polymer 
concentrations and for two of the non-solvent types tested (Figure 2.6). In water, for 
example, at 10 mg/ml polymer concentration, NPs size increased from 116.5 ± 0.9 to 
174.4 ± 1.2 nm as the ratio S/NS decreased from 0.5 to 0.05, respectively (mean ± SD, n=3 
for each formulation; p>0.05). For methanol the correlation is inverse than water, it was 
found that the higher solvent/non-solvent ratio, the bigger NPs; for example, at 50 mg/ml  
polymer concentration, NPs size decrease from 125.4 ± 1.7 to 73.63 ± 0.15 nm as the ratio 
S/NS decrease from 0.5 to 0.05, respectively. For the ethanol, no clear correlation 
between the NPs size and S/NS ratio was found. On the other hand, a clear dependence of 
the NPs size from polymer concentration in the diffusing phase, was observed for all the 
non-solvent types tested. When polymer concentrations were varied during NPs 
fabrication at a fixed S/NS ratio, an increasing NPs size with increasing polymer 
concentration is observed (Figure 2.6). For example, at 1:10 acetone/ethanol ratio, NPs 
sizes were 84.8 ±2.5, 102.7±0.47, 134.8±1.7 nm when the polymer concentration were 10, 
20, 50 mg/ml, respectively. Similar trends were observed in all other solvents investigated. 
Regarding polymer concentration has to be taken into consideration that a too high 
polymer concentration in the solvent prevented nanoprecipitation. This effect is probably 
due to the high viscosity of the polymeric solution that prevents an appropriate diffusion 
of the solvent toward the non-solvent. Other authors found also that the higher the 
polymer concentration in the solvent, the higher loss of polymer; they explained this 
effect in terms of the intrinsic viscosity and interaction constants 23. Also we studied the 
effects of varying formulations parameters on ζ potential. This is an important index for 
the stability of the NPs suspension. High absolute value of zeta potential indicates high 
electric charge on the surface of the NPs, which can cause strong repellent forces among 
particles to prevent aggregation 24. All NPs batches were found negatively charged with a 
value depending on the S/NS ratio and polymeric concentration. As shown in Figure 2.6 
the zeta potential ranged ̴ 20 mV for water,  ̴12 mV for methanol and ̴ 7 mV for ethanol. A 
clear correlation of ζ potential with formulation parameters was found for water; for a 
fixed polymer concentration, the lower the ratio S/NS, more negative the zeta potential. 
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When polymer concentration were varied during NPs fabrication at a fixed S/NS ratio, it 
was found that the higher polymeric concentration, less negative NPs. Higher negative 
value (-32 mV) was obtained at 10 mg/ml polymeric concentration and 1:20 S/NS ratio. 
Methanol exhibited the same correlation with ζ potential values moving in a narrow 
range. Lower negative value (-5 mV) was obtained at 50 mg/ml polymeric concentration 
and 1:2 S/NS ratio. As though for the size, no clear correlation between zeta potential and 
formulation parameters was found for ethanol. A ζ potential in this range is often 
observed in polyester nanoparticles and a value of about – 25 mV ensures a high-energy 
barrier that stabilizes the nanosuspension 25. 
 
 
. 
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Figure 2.6 Correlation of polymer concentration with NPs size and zeta potential (left and right column, 
respectively) at different solvent/non-solvent ratio (□ 1:20, Δ 1:10, ◊ 1:2) and for three non-solvent type. 
NPs size and z-potential determined by DLS; (n=3; errors bar not shown, SD≤2.5 nm for size and ≤1.8 mV for 
ζ) 
Size distribution and zeta potential 
All formulations formed monomodally distributed NPs in the desire range below 200 nm 
(Figure 2.6). The NPs size for all three non-solvent and for the investigated concentrations 
ranged from 70 to 200 nm and the size distribution was narrow with polydispersity in the 
range from 0.05 to 0.282. All formulations exhibited a net negative charge with ζ potential 
values ranging from -32 to -3 mV (Figure 2.6). 
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Optimized nanoprecipitation variables  
The initial approach to obtain PTX loaded NPs involved the choice of acetone and water as 
components of our nanoprecipitation based system. Acetone is not a concern in terms of 
toxicity, it belongs to Class 3 according to the ICH solvent toxicity scale (Class 3 solvent 
present very low risk to human health). Acetone has a low dielectric constant value which 
destines it a rather lipophilic drug encapsulation. The use of water as diffusing phase is the 
most appropriate; indeed the presence of the residual solvent is minimized only to 
residual acetone. In the following studies, the polymer concentration was fixed at 20 
mg/ml with acetone/water ratio as 1:20. The optimized NPs were further investigated by 
NTA and DLS. PTX-NPs size distribution is rather monodisperse with a mean of about 180 
nm, confirmed by NTA (Figure 2.7 a, c) and by DLS (Figure 2.7 b). No influence was exerted 
by PTX on the ζ potential value of NPs (-26 mV). 
 
Figure 2.7 PTX-NPs size distribution plots obtained by (A) NTA, (B) DLS and (C) NTA sample video frame of 
NPs moving under Brownian motion 
 
 
A C 
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Surface morphology  
The morphology images of the 3% PTX-NPs obtained from TEM indicate that the NPs can 
be estimated around 130-180 nm in size and are spherical in shape with a smooth surface. 
In the TEM photos, “PEG corona” on the NP surface could be observed (Figure 2.8). A 
further confirmation of the PEG corona surrounding NPs (marked in Figure 2.8 c with 
white arrow) was obtained by tilting angle experiments. The TEM carbon grid was tilted 
from 0º (Figure 2.8 c) to 45º (Figure 2.8 d); the PEG corona thickness remained 
unchanged, excluding a hypothetical aberration caused by the electrons beam interaction 
with the spherical surface (aberration occurred for the carbon grid spot marked with black 
arrow in Figure 2.8 c). An optimal external hydrophilic coating can improve stealthy 
behavior avoiding recognition by the reticuloendothelial system.  
 
Figure 2.8 TEM images of PTX-NPs (A, B)at different magnification and (C, D) PTX-NPs (white arrow) 
subjected to tilting angle experiments to assert PEG corona thickness remained unchanged; TEM carbon grid 
tilted from 0º (C) to 45º (D) 
C D 
A B 
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Drug incorporation efficiency 
The influence of the theoretical loading of PTX into P co-polymer NPs was examined. An 
increase in the theoretical loading from 2 to 20% w/w led to a corresponding increase in 
drug content from 3.8 ± 0.2 to 24 ± 3.5% w/w (Figure 2.9). Along with drug content, 
encapsulation efficiency was analyzed and as shown in Figure 2.9, the encapsulation 
efficiency remains constant approximately at 63 ± 0.7% with increasing theoretical PTX 
loading.  Our results are consistent with those reported by Danhier et al. 26, where 70% 
PTX E.E. into PLGA NPs was obtained with the nanoprecipitation methods. The results of 
this study are encouraging, because the drug contents are much higher than other 
polyester-based NPs 27. Generally, it was reported that the D.C. of PTX was about 3% in 
the nanoprecipitated NPs when the initial PTX loading was 4% (w/w) 27. Emulsioned PEG-
PLA NPs reported by Q. Hu et al. 28,29 reach a drug content ranging from 1 to 3 % along 
with an encapsulation efficiency of about 50%. When PLGA NPs are emulsioned with 
TPGS, which act as an emulsifier enhancing emulsification efficiency, PTX E.E. increases up 
to 80%, otherwise PTX D.C. does not exceed 3% 30.  
 
Figure 2.9 Drug Content (DC % w/w) and Encapsulation Efficiency (EE %) of PTX-NPs as a function of 
theoretical PTX loading 
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As shown in Table 2.2 moderate NPs recovery yield after freeze-drying was achieved, 
ranging from 47.5 ± 6.1 to 64.5 ± 7% for lower and higher theoretical PTX loading, 
respectively.  
Table 2.2 NPs recovery (%), D.C. (%) and E.E. (%) as a function of theoretical drug loading 
Theoretical drug  
loading % (w/w) 
NPs recovery  
(%) ± S.D. 
Drug Content % 
  (w/w)  ± S.D. 
Encapsulation Efficiency 
(w/w) % 
2 49,5 ± 4.2 3,8 ± 0.2 61,5 ± 1,7 
3 47,5 ± 6,1 4,2 ± 0.3 58,7 ± 1,6 
5 48,2 ± 3,9 7,6 ± 1.4 60,6 ± 1,3 
8 57,5 ± 6,7 10,4 ± 1.7 59 ± 1,9 
10 56 ± 7,1 13,1 ± 1.3 65,6 ± 2,3 
15 64,5 ± 7 19,8 ± 3.3 69,1 ± 2,8 
20 60 ± 6,8 24 ± 3.5 66,7 ± 3,1 
 
We hypothesize that high D.C. and PTX depending NPs recovery yield, are most likely due 
to the arrangement of the hydrophobic P co-polymer regions when forming NPs. Indeed, 
PTX acting as binding agent facilitates nanoprecipitation probably by increasing lipophilic 
interaction among hydrophobic P co-polymer blocks. Supposedly, polyester regions of the 
P co-polymer are in close contact to PTX while PEG groups are directed to NPs surface to 
interact with water. 
DSC 
To determinate the physical status of PTX inside NPs, DSC analysis was performed. The 
results are shown in Figure 2.10. Pure PTX showed an endothermic melting peak at about 
223ºC, shifted to lower temperature (210ºC) in the thermograph of the physical mixture. 
3% PTX-NPs did not show a melting peak, such as the free-drug NPs, demonstrating that 
the polymer inhibited the crystallization of PTX during NPs formation. Therefore, it could 
be assessed that the PTX in the NPs was in an amorphous or disordered crystalline phase 
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of a molecular dispersion or a solid solution state in the polymer matrix after the 
production. Increasing NPs drug content, PTX remains in amorphous phase for theoretical 
drug loading of 5%. The 15% PTX-NPs showed a sharp melting peak at about 230º C 
indicating that a fraction of PTX was crystalline and did not dissolve in the P co-polymer 
matrix. Therefore, while PTX in the 3 and 5% sample completely dissolved in P co-polymer 
matrix, phase separation between PTX and P co-polymer occurred for the 15% PTX-NPs 
sample. Our results are consistent with previous findings by Mu et al. 31 that phase 
separation and crystallization of hydrophobic drugs like PTX can occur in NPs at high drug 
loading. 
 
Figure 2.10 Differential Scanning Calorimetry (DSC) thermographs of PTX, free-drug NPs, 3, 5, 15 % PTX-NPs, 
and NPs/PTX as physical mixture (1:1 w/w) 
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In vitro drug release from PTX-NPs 
The release profile of PTX from different formulations are presented in Figure 2.11. For 
the different PTX loaded co-polymer NPs, the release pattern displayed an approximately 
first-order release, without initial burst and with a drug release reaching completion in 
approximately 12 days for 3% PTX-NPs. Figure 2.11 also shows PTX release profile in the 
first hours of test; it’s possible to appreciate that the release is very slow and constant 
with approximately 6.2% of PTX released in 3 hours from 3%-PTX-NPs. NPs with higher 
drug loading (10, 15 %) showed the same trend with a slower release and around of 60% 
of PTX was released in 12 days. Since NPs are prepared by the same co-polymer P, the 
difference in PTX percentage released can be explained as follows. For 10 and 15 % PTX 
loaded NPs, a considerable amount of drug is present in the bulk. This higher PTX content 
(w/w) in the polymeric matrix consequently bestow on NPs greater hydrophobic 
character, leading to slower release. Moreover the initial burst absence and the nearly 
linear behaviour demonstrate the absence of adsorbed drug on NPs surface. In vitro PTX 
release from polyester-based NPs usually present biphasic profile or very fast complete 
drug release. PHA (Poly Hydroxyalkanotes) and poly ε-CPL for example, released over 50% 
of PTX in the first hours 27,32. On the other hand PDLLA/PLGA PEG NPs exhibited a lower 
burst effect, but nevertheless the total cargo is released in 2 and 4 days, respectively 27,29, 
which, generally, is too fast to meet therapeutic needs. With respect to our PTX co-
polymer NPs, in vitro kinetic shows a release that is proportional to NPs co-polymer matrix 
degradation and depending on the total cargo, allows PTX to be released in a modulated 
and controlled way. This may be explained supposing PTX acts as binding agent, thus 
higher PTX weight content in the matrix material makes the NPs possess greater 
hydrophobic character, leading to limited water entry into the NPs core.  
 Chapter II - Synthesis and Characterization of Customizing Polymeric NPs for PTX Release 
49 
 
 
Figure 2.11 In vitro release kinetics of PTX from P co-polymer NPs at 3, 10, 15 % w/w theoretical drug 
content (PBS 0.1 M with 0.3 % v/v Tween-80, pH 7.4, 37º C) Mean ± SD (n=3) 
 
Along with in vitro drug release we also analyzed the degradation products of the NPs. 
Polyester-based NPs undergoes degradation by hydrolysis or biodegradation through 
cleavage of its backbone ester linkages into oligomers and, finally monomers. This has 
been demonstrated in both in vivo and in vitro 33,34. The degradation process for polyester-
based NPs is mainly through uniform bulk degradation of the matrix only where the water 
penetration into the matrix is faster than the rate of the polymer degradation. 
Furthermore, the increase of carboxylic end groups as a result of biodegradation 
autocatalysis the process. The presence of the drug may alter the degradation mechanism 
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combining bulk erosion with surface degradation, as well as affect the rate of matrix 
degradation. We studied the degradation of the NPs in terms of formation of polymer 
degradation products, to ensure that PTX release was related with polymer degradation, 
and it could not be attributed to a simple diffusion of the encapsulated drug through the 
polymer core matrix. Therefore, we tried to indirectly demonstrate that drug release is a 
good indicator of the polymer degradation. Analyzing the drug release medium by UPLC-
TOF-MS, at day 10, two groups of peaks, at high (Figure 2.12) and at low molecular weight 
(Figure 2.13) can be detected. 
 
Figure 2.12 UPLC-MS spectrum of release medium at day 10; (A) high-molecular weight distribution; (B) 
spectrum zoomed on 907.5272 peak 
Analyzing the mass spectrum (Figure 2.12 a) the product detected at high molecular 
weight can be identified as PEG with a molecular weight arount 1500 Da. This fact 
corroborated that PEG is one of the degradation byproducts of the polymer as expected. 
Also another family of peaks was identified with a molecular weight of 411.27 Da, as 
shown in Figure 2.13. This peak was identified as the hydrophobic polymeric chain of the 
polymer constituting NPs (see Figure 2.13) and confirms that the main mechanism of the 
polymer biodegradation is the hydrolysis of the polyester bond between the polyester 
block and the PEG moiety. These two families of degradation products were not found 
when the release medium was analyzed the first day of the release kinetic experiment.  
A B 
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Figure 2.13 UPLC-MS spectrum of release medium at day 10, low molecular weight distribution 
Characterization of emulsion-based PTX NPs 
Emulsioned NPs showed a size of 176.4 ± 2.5 nm with a polydispersity of 0.32 ± 0.02 and 
zeta potential of -39 ± 1.17 mV (Table 2.3). Unlike precipitated NPs, emulsioned NPs 
required lyoprotectant to assure optimal resuspension in water after freeze-drying. As 
shown in Table 2.3 various lyoprotectants were used and mannitol at 10% (w/v) allowed 
to obtain NPs with same characteristics prior to freeze-drying. Drug encapsulation studies 
showed an increase in drug content from 4 ± 0.4 to 11.7 ± 1 when the initial theoretical 
drug loading ranged from 3 to 12%. It’s important to notice that the drug content was 
referred to freeze-dried NPs recovered, so the values shown were not taking into account 
the NPs recovery yield (data not shown). The results were expressed as mean ± S.D. for 
three replicate samples. The results confirm the versatility of block co-polymer P and 
demonstrate its capacity to be employed as a drug delivery system. Indeed, satisfactory 
findings about size, PDI, zeta-potential and drug content were obtained by using 
nanoprecipitation as though emulsification-solvent evaporation techniques.    
HO
O
O
O
O
OH
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Table 2.3 Mean particle size and size distribution (PDI) of emulsioned NPs 
in the absence or presence of different lyoprotectant 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4 D.C. (%) of emulsioned NPS 
 
 
 
 
 
 
 
 
 
2.3.3 Cell experiments 
 
In vitro immunological assay  
Analyzing microscopic picture of the whole blood after NPs exposure, no change in 
morphology is observed on RBC’s, white cell and platelets (data not shown). Our results 
highlight that NPs and PTX-NPs are not haemolytic (<2%). In regards to cells counting, no 
significant change was observed in RBC’s, WBC’s and platelet counting at the 
concentration evaluated. Analyzing C3a concentration by ELISA assay, no significant 
activation of complement is observed in presence of the NPs suspension. Along with 
complement system, no relevant activation of coagulation by intrinsic or the extrinsic 
pathway was remarked.     
 
Lyoprotectant used and 
concentration % (w/v) 
Size 
(nm) ± S.D. 
PDI ± S.D. 
No freeze-dried 176,4 ± 2,5 0,32 ± 0,0 
No Lyoprotectant n.m. 1 
Sucrose, 10  220,2 ± 1,1 0,31 ± 0,02 
Glucose, 10 195,1 ± 5,6 0,46 ± 0,05 
Lactose, 5 211,9 ± 3,4 0,24 ± 0,00 
Mannitol, 10 175,5 ± 3,8 0,33 ± 0,05 
Pva, 2 66,5 ± 17 0,9 ± 0,1  
Theoretical Drug 
Loading (%, w/w) 
Drug Content 
%                                  
(w/w) ± S.D.                                           
3 4 ± 0.4 
4 6,2 ± 0.6 
8 8,2 ± 0.6 
10 9,1 ± 1.1 
12 11,7 ± 1 
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In vitro anti-proliferative efficiency 
The in vitro anti-proliferative effect of drug-free NPs and PTX-NPs on U-87 MG cells was 
evaluated using MTS assay and PTX as comparison. As shown in Figure 2.14 a and b no 
obvious cytotoxicity was observed for the drug-free NPs. The synthetized block co-
polymer (P) biocompatibility was confirmed since the drug-free NPs showed no decrease 
in cellular viability. Cells were incubated with 3, 5 and 8 % PTX-NPs at 10 and 20 nM PTX 
concentrations. This range of concentrations was selected because it corresponds to 
plasma levels of the drug achievable in humans. As can be seen in Figure 2.14 a, a marked 
reduction in cell viability (10%) was observed when U-87 MG cells were incubated 11 days 
with 3% PTX-NPs at 10 nM. For the same incubation time, PTX showed similar toxicity than 
3% PTX-NPs, otherwise for 5 and 8 % PTX-NPs a slighter effect was observed, with 76 and 
80% survival rate, respectively. With increasing PTX concentration at 20 nM, a significant 
reduction in U-87 MG cells viability was achieved in shorter incubation times and for all 
formulation tested. As shown in Figure 2.14 b, at this concentration the cell growth was 
strongly inhibited after 4, 8 and 11 days for 3, 5, 8 % PTX-NPs, respectively, with a 
reduction of approximately 50% in cell viability. Again, PTX at 20 nM showed similar effect 
on U-87 MG cells than 3% PTX-NPs, indicating that the developed PTX-NPs system did not 
decrease the PTX activity on tumoral cells and that the cytotoxicity against U87 MG cells 
was in time- and drug concentration-dependent manner.  
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Figure 2.14 Cell viability on U-87 MG incubated with PTX, NPs (drug free) and 3, 5, 8 % PTX-NPs at (A) 10 and 
(B) 20 nM PTX concentration after 11 days cell culture (n=3) 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
1 4 6 8 11
%
 S
u
rv
iv
al
Days
B
0
20
40
60
80
100
120
1 4 6 8 11
%
 S
u
rv
iv
al
Days
A PTX 3% PTX-NPs 5% PTX-NPs 8% PTX-NPs NPs
 Chapter II - Synthesis and Characterization of Customizing Polymeric NPs for PTX Release 
55 
 
2.4 Concluding Remarks 
We have developed a nanoparticluate system for controlled release of the anticancer drug 
PTX. A novel block co-polymer (P) was successfully synthetized to obtain via 
nanoprecipitation or emulsification-solvent evaporation method, a very monodisperse 
PTX-NPs population. A clear correlation between NPs characteristics and formulation 
parameters was found in order to entirely customize NPs in terms of size, zeta-potential, 
drug loading and release profile. Selected PTX-NPs showed a spherical shape with particle 
size of ̴180 nm, polydispersity of ̴ 0.1 and with a surrounding PEG corona on the surface. 
PTX content of NPs was easily increased up to 24% (w/w) limited only by the physical state 
change of the drug (amorphous < 15%). High D.C. makes the system suitable for 
intravenous administration since only low concentrated PTX solutions can be injected due 
to the side effects related to its vehicle. High D.C. was probably due to strong lipophilic 
interactions of PTX with hydrophobic inner region of NPs. Consequently, in vitro PTX 
release from NPs, exhibiting an approximately first-order profile, depended on total cargo, 
with complete release approximately in 12 days for 3% theoretically loaded NPs. Higher 
PTX loaded NPs, limiting water entry, showed a similar trend, characterized by absence of 
initial burst release but with a slower release of approximately 54% and 45% for 10% and 
15%, respectively, at day 9. In vitro cellular studies demonstrated that block co-polymer-
based NPs were biocompatible, and the PTX loaded NPs had significant in vitro anti-
tumoral activity against human primary glioblastoma cell line (U-87 MG). The cytotoxicity 
against U87 MG for PTX-NPs was time- and drug concentration-dependent. The developed 
NPs showed to fully accomplish all requirements for a proper drug delivery system but an 
efficacious targeting is required to improve therapeutic index and avoid the adverse effect 
of an uncontrolled release. In the next chapter (Chapter III) the suitability of the system 
for targeting NPs is investigated by functionalizing NPs surface with target-specific ligands. 
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3.1 Introduction 
The previous chapter (Chapter II) has shown the complete development and 
characterization of a tailored nanoparticulate system for controlled release of anticancer 
drug PTX. It has been demonstrated how NPs characteristics can be customized to obtain 
high PTX loaded NPs that can improve therapeutic index and avoid an uncontrolled 
release.  As discussed in Chapter I, NPs have several advantages as delivery vehicles that 
make them useful for cancer therapy. The small size for example, allows nanoparticles to 
overcome many biological barriers, access tumor tissue through porous vasculature 1,2, 
and achieve cellular uptake 3. However, a careful engineering of polymeric nanoparticles 
including functionalization with targeting ligands is needed to promote receptor mediated 
uptake into the cancer cells. 
 
In addition to NPs’ surface engineering to increase blood circulation and influence 
biodistribution 4, in recent years different investigations about targeting ligands attached 
to the surface and their effect on the uptake by target tissue have been carried out 5. 
Encapsulation of chemotherapeutic drugs inside targeted nanoparticles can further 
increase the therapeutic index by delivering an elevated dose directly to a tumor while 
limiting systemic toxicity 6. As described in Chapter I and II, NPs consist of several 
components (Scheme 3.1) that can be engineered based on the desired application. 
Considerations of each component are necessary when designing a delivery system 
because each component affects the overall performance of the system. In addition to the 
components discussed in the previous chapter (core, corona, and payload), this chapter 
describes the use of targeting ligands with the aim to enhance cellular uptake through 
binding and endocytosis. 
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Scheme 3.1 Components of a nanoparticle delivery system 
 
The global market for drugs for the central nervous system (CNS) is greatly 
underpenetrated and would have to grow by over 500% just to be comparable to the 
global market for cardiovascular drugs 7. As it has been described in Chapter I, the main 
reason for this under-development of the global brain drug market is that the great 
majority of drugs do not cross the brain capillary wall, which forms BBB in vivo. There are 
only a few diseases of the brain that consistently respond to lipide-soluble-low MW small-
molecule therapeutics 7–9.  In contrast, many other serious disorders of the brain, 
including neurodegenerative diseases, do not respond to conventional therapeutics. 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and brain tumors 
are now representing the largest and fastest growing area of unmet medical needs. 
Glioblastoma multiforme (GBM), one of the most malignant brain tumors, accounting for 
about 40% of all brain tumors, remains a big challenge due to its highly proliferative, 
infiltrative and invasive property. Advances in neuroscience have resulted in development 
of new therapeutic agents for potential use in the central nervous system (CNS). 
Unfortunately, the therapeutic effect of brain disorders by drug treatment (such as 
chemotherapy, essential in the auxiliary treatment of glioma) is limited by the presence of 
the BBB, which protects the CNS from potentially harmful molecules to ensure optimal 
environment for brain function, but at the same time, excludes more than 98% of small 
molecule candidates drugs and almost 100% of large molecule drugs 10,11. BBB 
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permeability is the rate-limiting factor for the penetration of pharmacological agents into 
CNS 12. The BBB is mainly formed by brain capillary endothelial cells (EC) that are closely 
sealed by tight junctions. Receptor-mediated endocytosis is one of the mechanism 
through which drug carriers cross the BBB. Different transporters and receptors present at 
the BBB have been described as playing roles in maintaining the integrity of the BBB and 
brain homeostasis. Among them, low-density lipoprotein receptor-related protein (LRP), a 
member of the low-density lipoprotein receptor family (LDLR), highly expressed on BBB 13, 
has been reported to possess the ability to mediate transport of ligands across EC of the 
BBB 13–15. Furthermore, LRP is also over-expressed on human glioma cells 16,17, making LRP 
a potential targeted receptor for brain tumor drug delivery systems, with dual-targeting 
capability for both BBB and glioma cells.  
The anticancer drug paclitaxel (PTX), isolated from the bark of Taxus brevifolia, has been 
proved effective in the treatment of a wide variety of tumors, among them GBM 18. 
However, the application of PTX is compromised due to its poor aqueous solubility and 
serious adverse effects associated with the solvent Cremophor EL-ethanol  19. 
Furthermore, nonspecific systemic distribution of PTX commonly gives rise to dose-
dependent toxic effects and poor therapeutic outcomes.  
 
To overcome these disadvantages, various drug delivery systems, such as liposomes 20, 
nanoparticles (NPs) 21,22, polymer drug conjugates 23 and micelles 24, have been developed 
from different viewpoints. Among them, biodegradable polymeric NPs in the range 70-200 
nm,  due to their loading capacity for highly insoluble drugs, have been successfully 
utilized to entrap PTX, achieving less PTX-associated side effects as well as better 
therapeutic benefits over commercial Taxol 25. Furthermore, surface modifications 
through physical absorption of a hydrophilic polymer synthesis or amphiphilic co-polymers 
were widely applied in order to develop long-circulating NPs, minimizing the absorption of 
opsonins and thereafter the removal from the blood 5,26. A series of hydrophilic polymers 
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have been attempted to decorate the NPs surface, such as poly(ethylene glycol) PEG 27,28 
or methoxy poly(ethylene glycol) (MPEG) 29. 
As a result, this chapter seeks to convert NPs into an effective target drug delivery system 
for efficiently transport and release active drug molecules. The developed strategy allows 
to select the target by functionalizing NPs with a family of peptides containing cysteine 
(Cys, C) residues, thus allowing an efficacious and targeted delivery with minimal systemic 
side effects due to nonspecific uptake by healthy tissues. In this chapter, a dual-targeting 
drug delivery system was developed by functionalization with a family of peptides, known 
to be efficiently transported across the BBB by LRP-mediated transcytosis, to shuttle drug 
from blood to brain, and then target glioma cells. 
 
In addition to the block co-polymer P discussed in Chapter II, a novel biodegradable block 
co-polymer 2P was synthetized. A nanoprecipitation technique with modification of a 
previously described (Chapter II) method was developed to obtain dual-targeting 
functionalized NPs with monodisperse particles size, external hydrophilic coating and high 
drug content for the anticancer drug PTX delivery.  
 
The physicochemical characterization involves in vitro release profile, cellular uptake and 
anti-glioma effect on human primary glioblastoma cell line (U-87 MG) and Bovine Brain 
Endothelial Cells (BBMVECs). Moreover, to confirm the dual-targeting effect, BBB crossing 
properties in vitro were investigated by transendothelial transport experiments in an in 
vitro BBB model, developed from the expertise of our group.  
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3.2 Experimental Section  
3.2.1 Materials 
1.8-Octanediol (98%) 2.2′-Dithiodipyridine (≥97%) and PEG (Mw 1.5 KDa) were purchased 
from Sigma (Sigma-Aldrich, USA). Glutaric acid (99%) was obtained from Alfa Aesar (USA). 
AGBBB015F (CGGKTFFYGGSRGKRNNFKTEEY) and Regulon (HKKWQFNSPFVPRADEPARKGKV 
HIPFPLDNITCRVPMAREPTVIHGKREVTLHLHPDH) peptides fluorescently labeled with 
carboxyfluorescein and 5-Tamra, respectively, were synthesized by Innovagen AB 
(Sweden). PEG Thiol acid, α-Thio-ω-carboxy poly (ethylene glycol) (MW 3.000 Da) was 
supplied by Iris Biotech GmbH (Germany). PTX (≥ 97%) was provided by Yunnan Hande 
Bio-Tech CO, LTD, P.R. China. FBS was purchased from Lonza (Spain), L-Glutamine and 
Penicillin/Streptomycin were provided by Labclinics. All other chemicals of analytical grade 
were purchased from Sigma (Sigma–Aldrich, Germany). 
 
3.2.2 Synthesis of peptide-conjugate Block Co-Polymer 2P  
Synthesis of Linker 
To an oven dried one-necked flask under nitrogen at RT equipped with a stir bar, 2,2’-
dithiodipyridine (MW:220.31, 66.4 mg, 2.14 mmol) in 5 ml THF and 0.5 ml AcOH purged 
with nitrogen was added. To this mixture, α-Thio-ω-carboxy poly (ethylene glycol) (MW 
3317 Da, 500 mg, 1.07 mmol) dissolved in few ml of THF was added dropwise. The 
solution turned yellow and was allowed to stir for three days.  After completion of the 
reaction, TLC analysis was performed, using 90% DCM and 10% MeOH to verify the 
presence of non-reacted 2,2’-dithiodipyridine. The product was then precipitated in 100 
ml of hexane under low magnetic stirring. The solution was refrigerated overnight at 8-
10°C and placed in conical tubes, and after a short vortex agitation two centrifuge cycles 
were performed, at 2700 g for 15’ and at 1300 g for 20’, respectively. After each cycle the 
supernatant was removed and analyzed by TLC, the same amount of hexane was added 
and a short vortex agitation to redisperse the pellet was performed. Residual solvent was 
Chapter III – NPs’ Peptide Functionalization and In Vitro evaluation of dual-targeting effect 
66 
 
removed under vacuum and to yield the product as a yellow solid (0.5165 g), which was 
analyzed using TLC under the above-mentioned conditions.  
Synthesis of 15F and Reg Peptide-Targeted Linker 
Sulfhydryls is present in AGBBB015F (15F) and REG peptides in the side-chain of cysteine 
(Cys, C) AA. Pairs of cysteine sulfhydryl groups were linked by disulfide bonds (–S–S–) to 
the linker. Sulfhydryl-reactive chemical groups include pyridyl disulfides that react with 
sulfhydryl groups at physiologic pH to form disulfide bonds. During the reaction, a 
disulfide exchange occurs between the molecules –SH group and the reagent's 
2-pyridyldithiol group; as a result, pyridine-2-thione is released. The coupling between Cys 
peptides and linker was carried out in 5 ml PBS (10 mM, pH 7.4) weighing accurately 1 mol 
of linker and 1.05 mol of peptide. The reaction was stirred at 0 °C for 4 hours. The 
progress of the reaction was monitored by TLC, showing total conversion of the starting 
material. The solution was lyophilized to yield Peptide-Targeted Linker as a white powder.  
 
Synthesis of pre-polymer P* and block co-polymer 2P 
The preliminary step was the production of pre-polymer P* which took place in the 
microwave reactor by reacting glutaric acid and 1.8-octanediol at a feeding ratio of 1:1.2 
(molar) at 100 W for 1 hour. The reaction was performed under the same conditions as 
described in Chapter II. In this way a pre-polymer P* was obtained with an excess of 1.8-
octanediol which can react with the linker. This last reaction took place in the microwave 
reactor with the same conditions above and with a ratio 1:1 (w/w) between preformed 
peptide-targeted linker and pre-polymer P*. 
 
Synthesis of fluorescently labeled 3P block co-polymer 
To an oven dried one-necked flask at RT equipped with a stir bar, 20 mol of α-Thio-ω-
carboxy poly (ethylene glycol) (MW 3073 Da) in 2 ml mQ water (pH 7) were added. To this 
mixture, 1 mol of the orange/red fluorescent dye (Alexa Fluor® 568) (MW 880.92 Da) 
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dissolved in few ml of water (pH 7) was added. The solution was allowed to stir for two 
hours. After completion of the reaction, TLC analysis was performed, using 70% DCM and 
30% MeOH to verify the presence of non-reacted α-Thio-ω-carboxy poly (ethylene glycol). 
Next step was the production of pre-polymer P* which took place in the microwave 
reactor by reacting glutaric acid and 1.8-octanediol at a feeding ratio of 1:1.2 (molar) at 
100 W for 1 hour. The reaction was performed under the same conditions as described in 
Chapter II. In this way a pre-polymer P* was obtained with an excess of 1.8-octanediol 
which can react with the fluorescently labeled α-Thio-ω-carboxy poly (ethylene glycol). 
This last reaction took place in the microwave reactor with the same conditions above and 
with a ratio 1:2 (w/w) between preformed fluorescently labeled α-Thio-ω-carboxy poly 
(ethylene glycol) and pre-polymer P*. 
 
3.2.3 Characterization of Block Co-Polymer (2P) 
The composition of the 2P block co-polymers was determined by proton nuclear magnetic 
resonance 1H-NMR in CDCl3 at 300 MHz (Varian 400 MR). The weight-averaged molecular 
weight (Mw) and molecular weight distribution (P.I. = polydispersity index) of the 
obtained polymers were determined by gel permeation chromatography (GPC) using a 
LaChrome Elite chromatograph (Hitachi) equipped with a refractive index (RI) detector. A 
Shodex KF-603 column was used as stationary phase, and HPLC grade THF was used as the 
mobile phase at a flow rate of 0.5 ml/min. The samples were dissolved in THF and filtered 
previous to injection (injection volume = 20 µl). The molecular weights of the copolymers 
were determined relative to the standards curve, prepared using a series of Shodex SM-
105 polystyrene standards. MALDI-TOF mass spectra were determined using a Microflex – 
Bruker Daltonics (Bruker Corporation, Germany). Polymer samples were spotted for 
analysis using a dried-droplet method. For each sample, the polymers were first dissolved 
in a TA solution of water, acetonitrile and TFA (50%, 50% and 0.1%, respectively). A fresh 
saturated solution of matrix material was prepared by mixing the matrix powder of ACCA 
(α-Cyano-4-hydroxycinnamic acid) with TA solution. Then 100 µl of the supernatant matrix 
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solution was mixed with the 10 µl of sample. A 1 µl droplet of the resulting mixture was 
placed on the mass spectrometer’s sample stage, and then the droplet was dried at room 
temperature. 
 
3.2.4 Preparation of 15F and REG peptide-functionalized PTX-NPs  
The nanoprecipitation technique was applied to prepare peptide-functionalized PTX-NPs 
with modification of the method reported in Chapter II. Briefly, block co-polymers P, 2P 
and if required 3P, at different ratio (w/w) and PTX were dissolved in 1 ml of acetone to 
form the diffusing phase.  This phase was then added to 20 ml of milliQ water, by means 
of a syringe, controlled by a syringe pump (KD Scientific), positioned with the needle 
directly in the medium, under magnetic stirring at room temperature. The resulting 
nanoparticles suspension was allowed to stir uncovered to allow the evaporation of 
acetone. Drug free nanoparticles were prepared according to the same procedure. The 
suspension was purified by centrifugation (Hettich Centrifuge, EBA 21, 4000 g, 45 min at 
RT) with ultracentrifugal devices (Amicon Ultra-15, Ultracel membrane with 100,000 
MWCO, Millipore, USA). The supernatant was discarded and the pellet freeze-dried for 48 
hours.   
 
3.2.5 Characterization of 15F and REG-functionalized-PTX-NP 
Size, morphology and zeta potential 
The NPs size distributions and polydispersity were measured by dynamic light scattering 
(Malvern Zeta Sizer Nano Series) at 25ºC and at scattering angle of 90º using samples 
appropriately diluted with mQ water. For each sample the intensity-weighted mean value 
was recorded as the average of three measurements. The results were expressed as mean 
± standard deviation (mean ± S.D) for two replicate samples. Further measurements were 
performed by nanoparticles tracking analysis (NTA, Nanosight LM 10, Laser Module LM 
14C), with a 532 nm laser beam passed through a prism-edged optical flat and validating 
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all data with video files of the NPs moving under Brownian motion to determinate NPs 
size distribution and to confirm the monodispersity of the NPs solution. NPs were also 
characterized with respect to zeta (ζ) potential, the analysis was performed in triplicate on 
Malvern ZetaSizer (Nano Series) with a Smoluchowsky constant F (Ka) of 1.5 to achieve 
zeta potential values from electrophoretic mobility. For each sample the mean zeta 
potential was recorded as the average of three measurements. The results were 
expressed as mean ± S.D for two replicate sample. The size and morphology of the NPs 
were observed by Transmission Electron Microscopy (TEM) (Jeol Jem 2011). A drop of the 
NPs suspension (10 µl) was placed on carbon electron microscopy grids (Holey Carbon 
Film) and air-dried before analyze at an acceleration voltage of 200 kV without negative 
staining. 
 
Drug encapsulation efficiency 
Freeze-dried NPs loaded with PTX were dissolved in acetonitrile and the amount of 
entrapped drug was detected by UPLC (Waters ACQUITY UPLC H-Class). A reverse phase 
BEH C18 column (1.7 µm 2.1 x 50mm) was used as stationary phase. The mobile phase 
consisted of a mixture of acetonitrile and water (60:40 v/v) at a flow rate of 0.6 ml/min. 
Paclitaxel was quantified by UV detection (λ=227 nm, Waters TUV detector). A calibration 
curve of standard paclitaxel solution was used to obtain the paclitaxel concentration, 
which was linear over the range of 60.5 – 0.47 µg/ml with a correlation coefficient of 
R2=0.9998. Drug incorporation efficiency was expressed as drug content (% w/w) and drug 
entrapment (%); represented by Equation 3.1 and Equation 3.2, respectively. For each 
sample the mean value was recorded as the average of three measurements. The results 
were expressed as mean ± S.D for two replicate. 
Drug Content (%
w
w
) =
Mass of drug in NPs × 100
Mass of NPs recovered
 
         Equation 3.1                                                                                                                           
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Drug Entrapment(%) =
Mass of drug in NPs × 100
Mass of drug used in formulation
 
Equation 3.2                          
Thermal characterization 
The physical state (crystalline versus amorphous) and miscibility of Paclitaxel in the NPs 
were characterized by differential scanning calorimetry (DSC Mettler Toledo DSC821e) on 
glass transition temperature (Tg) or melting point (Tm). Pure paclitaxel was analyzed as the 
control. Experimentally, 4-5 mg of each sample were sealed in a standard aluminum pan 
and purged with dry nitrogen at a flow rate of 50 ml/min while the sample was heated 
from 50ºC to 300ºC (temperature ramp of 10ºC/min). 
In-vitro PTX release 
In vitro drug release from PTX loaded NPs was performed using a modified dialysis-bag 
diffusion technique, as reported by Kim et al. and Averineni et al. 30,31. Specifically, a 
known amount of freeze-dried peptide-functionalized-PTX-NPs, corresponding to 0.3 mg 
of PTX, was suspended in a dialysis bag (regenerated cellulose tubular membrane, Cellu 
SEP® T2, nominal MWCO 6000–8000, membrane filtration products, Inc, TX) containing 15 
ml of release PBS solution (0.1 M at pH 7.4 and 0.3% v/v of Tween-80). The bag containing 
NPs suspension was placed in a 50 ml Eppendorf® Tube (Fisher Scientific Company, 
Houston, TX) containing 30 ml of release medium (PBS solution and 0.3% v/v of Tween-
80). The whole system was then placed in an orbital shaking incubator (LM-450D, Yihder 
Co., Ltd) at 37°C and at shaking speed of 200 rpm. At pre-decided time points, 1 ml 
aliquots of release medium were withdrawn and replaced with an equal volume of fresh 
medium to maintain the sink conditions. Aliquots were filtered through a 0.2 µm syringe 
filter directly into UPLC vials and immediately capped. The amount of PTX released in each 
time interval was determined by UPLC with a reverse phase BEH C18 column (1.7 μm 
2.1×50 mm) as stationary phase and a mixture of Acetonitrile/Ammonium Acetate Buffer 
(20 mM, pH 4.5) = 60/40 at a flow rate of 0.6 ml/min as the mobile phase. PTX was 
quantified by UV detection (λ=227 nm, Waters TUV detector); the reported values are 
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averages ± S.D. of three replicates. The percent drug release was calculated as percentage 
of the total encapsulated drug.  
 
Peptide-conjugation efficiency by Fluorometric assay  
To quantify 15F and REG peptide on the NPs surface, lyophilized NPs solutions at c.a. 15 
mg/ml were analyzed by using a fluorimeter (Horiba Scientific, Fluoromax-4). Intensity and 
wavelength distribution of the emission spectrum after excitation at λexc = 400 nm (15F) 
and 500 nm (REG peptide) were studied. For each sample the intensity mean value was 
recorded as the average of three measurements. 15F and REG conjugation efficiency (CE 
%) was calculated using Equation 3.3, in order to determine the percentage of peptide 
conjugated to the NPs surface. 
 
Conjugation Efficiency(%) =
Amount of peptide conjugated on the NPs surface
Total amount of peptide added
 
Equation 3.3 
Peptide-conjugation efficiency by Amino Acids analysis 
Quantification of REG peptide decoration onto NPs surface was carried out by UPLC amino 
acids analysis. The Waters UPLC Amino Acid Analysis (AAA) Kit is based on a derivatizing 
reagent for amino acid analysis. 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate is an 
N-hydroxysuccinimide-activated heterocyclic carbamate, a class of amine-derivatizing 
compounds. 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate converts both primary 
and secondary amino acids to stable derivatives. Prior to the analysis, REG-functionalized-
PTX-NP were hydrolyzed in 6M HCl (20 hours, 110ºC) at peptide concentration 1 mg/ml, 
followed by evaporation of HCl under N2 and reconstituted in 0.1M HCl with borate buffer 
and then with derivatizing agent. Derivatization was carried out at 55ºC for 10 minutes. 
Analytical UPLC was performed using an ACCQ-TAG column ULTRA C18 (1.7 µm 2.1 x 
100mm) in UPLC Waters ACQUITY UPLC H-Class. The parameters of analysis, eluents and 
gradient are shown in Table 3.1. Amino acids identification and quantification were 
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determined relative to the calibration standard obtained by internal method. Briefly, to 
prepare a 2.5 mM internal standard stock solution of norvaline, 2.94 mg of norvaline were 
added to 10 mL 0.1 N HCl. Mix 70 μl of Ultra Borate buffer with 10 μl of calibration 
standard and 20 μl of reconstituted derivatizing agent, and vortex for several seconds 
before heating the vial for 10 minutes at 55 °C. 
Table 3.1 Gradient table for hydrolyzed sample. Eluent: (A) 0.1% Formic Acid/water, (B) Water/acetonitrile 
(90:10 v/v), (C) Water, (D) Acetonitrile. Detection wavelength 260 nm, flow rate 700 µl/min 
STEP TIME (min) % A %B % C % D 
1 0.00 10.0 0.0 90.0 0.0 
2 0.29 9.9 0.0 90.1 0.0 
3 5.49 9.0 80.0 11.0 0.0 
4 7.10 8.0 15.6 57.9 18.5 
5 7.3 8 15.6 57.9 18.5 
6 7.69 7.8 0.0 70.9 21.3 
7 7.99 4.0 0.0 36.3 59.7 
8 8.59 4.0 0.0 36.3 59.7 
9 8.68 10.0 0.0 90.0 0.0 
10 10.20 10.0 0.0 90.0 0.0 
 
3.2.6 Cell experiment 
Cell culture 
Bovine Brain Endothelial Cells (BBMVECs) and attachment factor solution were purchased 
from Cell Applications. U-87 MG (glioblastoma-astrocytoma) cells were provided by ATCC 
(Spain). Both were cultured in DMEM (Sigma, D5671) and FBS (Lonza, DE14-801F) 
containing L-Glutamine (PAA, M11-004), Penicillin/Streptomycin (PAA, P11-010) and 
Fibronectin (Sigma). Rat Astrocytes (RA) and astrocyte culture medium (AM) were 
provided by Innoprot. Rabbit monoclonal to RP1 (Anti-LRP1 antibody) and Alexa Fluor® 
488 Goat Anti-Rabbit antibody were purchased from AbCam and Invitrogen, respectively.  
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Hemocompatibility test  
Hemocompatibility of 15F and REG-functionalized-NPs loaded and not loaded with PTX 
was evaluated by diluting NPs in PBS at concentrations of 100 µg/ml. Hemocompatibility 
test was carried out after blood exposure (according to ISO 10993-4). Interaction of NPs 
with blood was analyzed during 15 minutes at 37ºC using normal human plasma collected 
under citrate. Firstly, microscopic pictures of the whole blood after NPs exposure were 
analyzed. Next, the hemolysis test was performed according to ASTM (Standard practice 
for assessment of haemolytic properties of materials, American Society for Testing and 
Materials Designation: ASTM: F 756-00) adopting Drabkin’s method. According to ASTM, 
<2% is considered as non haemolytic; 2-5% slightly haemolytic and >5% haemolytic. 
Further experiments included blood cell counting (Cell-Dyn Emerald 18, Abbott) and 
quantification of complement activation by determining the C3a concentration (ELISA kit). 
Finally, analysis of the activation of the coagulation either by the intrinsic (TCA test) or the 
extrinsic (Quick) pathways was performed. Analysis of the coagulation through the 
intrinsic and extrinsic pathway was performed under standard conditions of operation in 
clinical biology, i.e. with the addition of kaolin and thromblastin, respectively as activator 
of this biological cascade. This methodology allows to verify if the factors associated with 
this cascade are adsorbed or denaturated by the NPs. A reduction of the % corresponds to 
an inactivation of this coagulation pathway.  
 
LRP-1 expression in targeted cells  
LRP-1 expression was evaluated in U-87 MG and BBMVECs of the BBB by 
immunofluorescence techniques. U-87 MG and BBMVECs were seeded at a density of 
2000 cells/cm2 in a 24-well plates and incubated for 24 hours. Then the media was 
aspirate off, cells washed with PBS, fixed with 10% formalin for 20 minutes at RT and 
washed again for three times with PBS and permeabilized with 0.1% Triton X-100 in PBS 
for 10 minutes. Cells were then incubated with specific primary antibody (rabbit anti-LRP1, 
1:200; Abcam, Cambridge, UK) in PBS/0.1% Triton X-100/1% bovine serum albumin (BSA) 
Chapter III – NPs’ Peptide Functionalization and In Vitro evaluation of dual-targeting effect 
74 
 
overnight at 4º C. After washing cells six times with PBS/0.1% Triton X-100 incubation with 
specific secondary antibody (Alexa Fluor 488 goat anti-rabbit, 1:300; Invitrogen, Carlsbad, 
CA) for 1 hour at RT was carried out. After last cell washing with PBS solution, cell nuclei 
were counterstained with Vectashield commercial mounting medium containing DAPI. 
LRP1-1 expression in immunostained cells was observed with a ZEISS Axiovert 200M 
microscope. Images were taken with a Zeiss Axiocan MRm. In a qualitative experiment, 
the abilities of cellular internalization and the interaction of peptide-functionalized-NPs 
with LRP-1 were visualized under a fluorescent microscope, using fluorescently labeled 
peptides as the fluorescent probe.  
 
In vitro cellular uptake of peptide functionalized-PTX-NPs 
PTX loaded and peptide-functionalized NPs uptake by BBB endothelial cells and glioma 
cells was analyzed. BBMECs and U-87 MG cells were seeded at 20000 cells/cm2 density in 
24-well plate and incubated for 24 hours at 37ºC and 5% of CO2. After checking the 
confluence and the morphology, cell culture media was removed, cells were washed three 
times with PBS and treated with NPs solution at a concentration of 250 µg/ml (DMEM 
without FBS) for 30 minutes at 4ºC and 37ºC. After the incubation, cells were washed 
three times with PBS, fixed with 10% formalin solution for 20 minutes, cell nuclei 
counterstained with DAPI and examined under a fluorescence microscope 
(ZEISS Axiovert 200M). Images were taken with a ZEISS Axiocam MRm. In a separate 
experiment, to study LRP-1 expression concurrently with cellular uptake, U-87 MG cells 
were incubated for 30 minutes in the presence of peptide-functionalized-NPs at 37ºC for 4 
hours. The cultures were then fixed, immunostained for LRP-1 as described above, and 
then subjected to fluorescent microscopy analysis. 
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NPs toxicity study on glioma, neuroblastoma, endothelial cells and glia 
 
 MTS on glioma cell line (U-87 MG) 
In order to evaluate the cytotoxicity of the REG-PTX-NPs on glioma cell line (U-87 MG), the 
cells were grown in DMEM supplemented with 10% FBS, 1% L-Glutamine and 1% 
Penicillin/Streptomycin and plated in 96-well plates at a cellular density of 30.000 cells/ml. 
After 24 h, medium was aspirated and substituted with 100 µl at 20 nM PTX concentration 
of PTX-NPs and REG-PTX-NPs suspensions. Empty NPs were also examined with the 
concentration corresponding to that of 10 nM of PTX. Cells with PTX at 20 nM were used 
as positive control; cells without NPs were used as the negative control. After 1, 4, 6 and 8 
days, cell viability was assessed via MTS assay following the manufacturer instructions. 
Briefly, cells are washed with PBS and incubated with a solution of the MTS reagent and 
complete media at 37ºC. The absorption (A), which represented cell viability was 
measured via a microplate reader (Spectramax M2e) at the wavelength of 490 nm. Cell 
viability was calculated by Equation 3.4 and the errors bars were obtained from triplicate 
samples 
Cell viability (%) =
A𝑠𝑎𝑚𝑝𝑙𝑒 −  𝐴𝑏𝑙𝑎𝑛𝑘  
A𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑙𝑎𝑛𝑘
× 100 
 Equation 3.4 
 
 MTT on BBMVECs, human neuroblastoma cell line (IMR-32) and rat 
glial cells 
 
The cells were plated in 96-well plates and after that the medium was aspirated, NPs, 15F-
NPs and REG-NPs solutions were added. Cells without NPs were used as negative control; 
cells without NPs and treated with sds were used as the positive control. After 24 hours 
cell viability was assessed via MTT following the manufacturer instructions. Briefly, cells 
are washed with PBS and incubated with a solution of the MTT reagent and complete 
media at 37ºC for two hours. The absorption (A), which represented cell viability was 
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measured via a microplate reader (Spectramax M2e) at the wavelength of 540 nm. Cell 
viability was calculated as before described by the Equation 3.4 . 
. 
 Generation of reactive oxygen species (ROS) test on BBMVECs, 
human neuroblastoma cell line (IMR-32)  and rat glial cells 
 
Generation of reactive oxygen species (ROS) is inevitable for healthy cells and occurs at a 
controlled rate. Under conditions of oxidative stress (e.g. toxicity), ROS production is 
dramatically increased, resulting in subsequent alteration of membrane lipids, proteins, 
and nucleic acids. Different cell lines seeded on 24 well/plates were exposed to the NPs 
solutions (NPS, 15F-NPs and REG-NPs) at a concentration of 0.25 and 0.5 mg/ml. After 
incubating cells at 37° C for 24 h, cells were washed with PBS and incubated with a PBS 
solution of the Dichloro-dihydro-fluorescein diacetate (DCFH-DA) reagent (5 µM) at 37ºC 
for half hour. When DCFH (commonly known as dichlorofluorescin) enters the cells, 
cleavage of the diacetate groups following enzymatic or base-catalyzed occurs and a rapid 
oxidation to the highly fluorescent product dichlorofluorescein (DHF) takes place. The 
fluorescence was then analysed by flow cytometry. Cells without NPs were used as 
negative control; cells without NPs and treated with doxorubicin were used as positive 
control. The results were expressed as mean ± standard deviation (mean ± S.D) for three 
replicate samples (n=6). 
 
 Annexin A5 affinity assay on BBMVECs, human neuroblastoma cell 
line (IMR-32) and rat glial cells 
 
Apoptosis is a carefully regulated process of cell death that occurs as a normal part of 
development. In normal live cells, phosphatidylserine (PS) is located on the cytoplasmic 
surface of the cell membrane. However, in apoptotic cells, PS is translocated from the 
inner to the outer leaflet of the plasma membrane, thus exposing PS to the external 
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cellular environment.  The human anticoagulant, annexin V, has a high affinity for PS. 
Annexin V labelled with a fluorophore (Alexa Fluor® 488) can identify apoptotic cells 
providing an assay for apoptosis. Different cell lines seeded on 24 well/plates were 
exposed to the NPs solutions (NPS, 15F-NPs and REG-NPs) at concentration of 0.25 and 0.5 
mg/ml. After incubating cells at 37° C for 24 h, cells were washed with PBS and incubated 
with a water solution of annexin V (10 mM HEPES, 140 mM NaCl, 2,5 mM Cacl2,  pH 7.4) 
at 5 µL annexin V for 100 µL cellular suspension and at  RT for half hour. Finally, cells were 
washed with PBS and 1 µL of propidium iodide (PI) in annexin solution was added before 
flow cytometry. Cells without NPs were used as negative control; cells without NPs and 
treated with doxorubicin were used as positive control. The results were expressed as 
mean ± standard deviation (mean ± S.D) for three replicate samples (n=6). 
 
Transendothelial transport experiments by NTA and UPLC 
To provide an in vitro model of BBB for studying brain capillary functions, a system of co-
culture that closely mimics the in vivo BBB was developed. The endothelial cells were 
seeded onto polycarbonate filters (Transwell insert), that were placed in the wells 
containing astrocytes (no-contact). Primary culture of fresh astrocytes were plated in AM-
a culture medium and when confluence reached 80-90%, astrocytes were seeded in a 6-
wells plate (125.000 cells/well, 2ml). When the cellular confluence reached 60-70%, 
bovine Brain endothelial cells were seeded in Transwell insert (1 µm pore for a six well 
plate, 150000-200000 cells per insert) after coating surface. The co-culture was 
established after 48-72 hours aspirating astrocytes medium and transferring the Transwell 
insert into the wells so as to obtain a luminal and abluminal compartment. In order to 
assess the barrier integrity, BBB models were characterized in terms of trans-endothelial 
electrical resistance (TEER measurement after 72 h from the co-culture establishment, 
each measure per triplicate) and permeability (Pe) of the water-soluble molecular tracer 
Lucifer Yellow (LY). Transport from the luminal to abluminal compartment was performed 
as follows. PTX loaded REG-targeted and non-targeted NPs were suspended in Ringer’s 
solution at concentration of 250 µg/ml. 1.5 ml of NPs solution were incubated in the 
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luminal compartment of the BBB for 60 minutes at 37ºC and with 5% of CO2. 2.5 ml of 
Ringer’s solution was add in the abluminal compartment. Samples were collected from 
both compartments, at the beginning and at the end of the experiments and NPs 
concentrations were measured by NTA and by UPLC with the experimental conditions 
described in drug encapsulation efficiency section. An insert without cells was used as 
blank. 
 
Transendothelial transport experiments by fluorimetry 
In a separate transendothelial transport experiment, performed at Centro Tecnologico 
GAIKER-IK4, Zamudio, Spain, two in vitro BBB models employing endothelial and bend3 
cells, respectively, were developed. A system of co-culture was established and 
3P-fluorescently-labeled NPs, 15F-NPs and REG-NPs suspended in RHB + 0.5% BSA 
medium at 0.25 and 0.5 mg/ml concentrations, were incubated in the luminal 
compartment of the BBB model for 60 minutes. Moreover, in order to verify that NPs do 
not affect the barrier integrity, the permeability of the water-soluble molecular tracer 
Lucifer Yellow (LY) was studied. The permeability of NPs and LY through endothelial cells 
monolayer was determined  
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3.3 Results and Discussion 
3.3.1 Synthesis and Characterization of Block Co-polymer (2P) 
Block co-polymer 2P was synthetized by polycondensation of the linker (2,2’-
dithiodipyridine and α-Thio-ω-carboxy poly-ethylene glycol) coupled to peptide by 
disulfide bonds, and pre-polymer P* (1.8-octanediol and glutaric acid, 1.2:1 molar) in a 
microwave reactor, under vacuum, at 120°C and 100 W and with a ratio 1:1 (w/w) 
between preformed peptide-targeted linker and pre-polymer P* (Scheme 3.2).  
The composition of linker, P* and 2P co-polymers is confirmed by 1H-NMR. The linker 
polymer structure is confirmed by the corresponding 1H-NMR spectra (Figure 3.1). The 
four typical signals of the pyridyl group are shown at the aromatic region between 6.5 
ppm and 8.0 ppm (peaks a to d). The other proton signals refer to the different methylene 
groups present in the polymer structure. N-methylene protons of the amide group appear 
at 3.81 ppm as a multiplet (peak e) deshield due to the electronegativity of the near 
nitrogen. The signal corresponding to the PEG 1500 is shown as an intense singlet at 3.64 
ppm as expected (peak f), with an integration number of 369H referred to the protons of 
the pyridyl group. Methylene groups directly attached to the PEG group are evidenced at 
3.46 ppm (peak g) and 3.37 ppm (peak h) both as multiplets, at the amide group and 
carboxylic group sides, respectively. Protons on the β-carbon of the carboxylic acid appear 
as different signals as they are not magnetically equivalent, at 3.07 ppm and 2.96 ppm 
(peak i). Signals at 2.63 ppm and 2.37 ppm correspond to the protons on the α-carbon of 
the amide (peak j) and carboxylic acid (peak k), respectively. Finally, the most upfield 
protons appear at 1.86 ppm as a multiplet (peak l). 1H NMR (400 MHz, Methanol-d4) δ 8.42 (td, J = 
4.7, 2.4 Hz, 1H, a), 7.88 – 7.78 (m, 1H, b), 7.77 – 7.66 (m, 1H, c), 7.28 – 7.21 (m, 1H, d), 3.81 (m, 2H, e), 3,64 
(s, 369H, f) 3.46 (m, 2H, g), 3.37 (td, J = 5.5, 2.5 Hz, 2H, h), 3.07 (t, J = 7.1 Hz, 1H, i), 2.96 (t, J = 7.2 Hz, 1H, i), 
2.63 (td, J = 7.2, 6.4 Hz, 2H, j), 2.37 (t, J = 7.4 Hz, 2H, k), 1.86 (m, 2H, l). 
The P* structure is confirmed by the corresponding 1H-NMR spectra (Figure 3.2). Signals 
corresponding to the protons of the methylene groups attached to heteroatom are 
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observed at 4.08 ppm and 3.54 ppm, connected to the ester group (peak a) and to the 
hydroxyl group (peak b), respectively. Protons on the α-carbon of carboxylic acid and ester 
groups appear as a complex multiplet at 2.38 ppm (peak c), while the protons of the 
carbon atom on β-carbonyl appear as a multiplet at 1.90 ppm (peak d). The methylenic 
groups of the hydroxyl chain non-directly connected to heteroatom appear at 1.64 ppm 
(peak e) and 1.53 ppm (peak f), which corresponds to the most external groups, and at 
1.36 ppm (peak g) as an intense signal, which corresponds to the central methylenic 
groups. 1H NMR (400 MHz, Methanol-d4) δ 4.08 (t, a), 3.54 (t, b), 2.38 (m, c), 1.90 (m, d), 1.64 (m, e), 1.53 
(m, f), 1.36 (m, g). 
As the corresponding 1H-NMR reveals (Figure 3.3), the aromatic signals of the pyridyl 
group are not observed in the spectra of the 2P polymer. The signals corresponding to P* 
polymer are present in the spectra, and the peak corresponding to the protons of the 
methylene adjacent to the terminal alcohol has disappeared, as expected, due to bond 
formation with linker. Moreover, presence of PEG in the polymer is confirmed by the 
appearance of a peak at 3.50 ppm. 1H NMR (400 MHz, DMSO-d6) δ 3.99 (t), 3.50 (s), 2.31 (t), 2.23 (t), 
1.73 (m), 1.54 (m), 1.39 (m), 1.26 (s). 
The weight-averaged molecular weight and molecular weight distribution of the obtained 
P* and REG-2P co-polymer were determined by means of GPC. The molecular weights 
were found to be 1069 and 10299 for the P* and REG-2P copolymers, respectively. The 
PDI was narrow, which was around 1.8 for the P* co-polymer and 1.4 for the REG-2P co-
polymer. To verify the correct assignment of the peak fractions, the average molecular 
weight determination of the fractions was performed by MALDI-TOF mass spectroscopy. 
All mass spectra showed one major peak in agreement with the GPC profiles. The 
obtained experimental molecular weights were approximately 1000, 3000, 7300, 10200 
for P* (Figure 3.4), linker (Figure 3.5), 15F-2P (Figure 3.6) and REG-2P (Figure 3.7), 
respectively. 
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Scheme 3.2 Synthesis by polycondensation of block co-polymer 2P 
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Figure 3.11H-NMR spectra of Linker 
 
Figure 3.2 1H-NMR spectra of P* block co-polymer 
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Figure 3.3 1H-NMR spectra of 2P block co-polymer 
 
 
Figure 3.4 MALDI-TOF mass spectroscopy of P* block co-polymer 
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Figure 3.5 MALDI-TOF mass spectroscopy of linker 
 
Figure 3.6 MALDI-TOF mass spectroscopy of 15F-2P block co-polymer 
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Figure 3.7 MALDI-TOF mass spectroscopy of 15F-REG block co-polymer 
 
3.3.2 Characterization of 15F and REG-functionalized-PTX-NPs 
Morphology, particle size, size distribution and zeta-potential 
The modified nanoprecipitation approach proposed for the preparation of peptide-
functionalized PTX-NPs is shown in the schematic illustration of Scheme 3.3. In this 
process, the organic phase containing preformed block co-polymers P and 2P was co-
precipitated with PTX into the aqueous phase to form NPs. The particle size, polydispersity 
and morphology are shown in Figure 3.8. The average diameter of NPs determined by DLS 
and NTA was 180 nm with a PDI of 0.1 (Figure 3.8 A, B, D). The zeta potential for both 
peptide functionalized-PTX-NPs was about -32±1.5 mV. TEM images (Figure 3.8 C) 
revealed that the NPs were dispersed as individual NP with a well-defined spherical shape 
surrounded by PEG-corona and homogenous distribution around 200 nm in diameter, 
without any adhesion or aggregation. 
 
3
4
8
9
.7
0
5
6
9
1
3
.6
7
2
5
1
1
1
.8
9
6
1
0
2
2
2
.5
4
3
0
1000
2000
3000
In
te
n
s
. 
[a
.u
.]
2000 4000 6000 8000 10000 12000 14000 16000 18000
m/z
Chapter III – NPs’ Peptide Functionalization and In Vitro evaluation of dual-targeting effect 
86 
 
Drug efficiency and Differential Scanning Calorimetry (DSC) 
As described by the previous Chapter with PTX-NPs (without 2P block co-polymer), an 
increase in PTX theoretical loading led to a corresponding increase in D.C. (% w/w) with 
E.E. (%) remaining approximately constant. The D.C. of peptide-functionalized-PTX-NPs 
was confirmed about 4 % and 7 % when the PTX theoretical loading was 3 and 5%, 
respectively. Higher D.C. than other polyester-based NPs 32 is most likely due to the 
arrangement of the hydrophobic P and 2P co-polymers regions when forming NPs. Indeed, 
PTX acting as binding agent facilitates nanoprecipitation probably by increasing lipophilic 
interaction among hydrophobic co-polymers blocks. Supposedly, polyester regions of the 
P and 2P co-polymers are in close contact with PTX while PEG groups are directed to NPs 
surface to interact with water. DSC showed the existence of the PTX, formulated in the 
peptide-functionalized-PTX-NPs at 3 and 5% PTX theoretical loading, in an amorphous 
state or solid solution in the polymeric matrix. 
In vitro PTX release 
The release profile of PTX from 3 % PTX loaded peptide-functionalized-NPs in PBS 0.1 M 
with 0.3 % v/v Tween-80, at 37ºC is presented in Figure 3.9. The release pattern displayed 
an approximately first-order release, without initial burst and with a drug release reaching 
completion in approximately 12-13 days. The release was very slow and constant with 
approximately 19 % of PTX released in 24 hours. The initial burst absence and the nearly 
linear behavior demonstrate the absence of adsorbed drug on NPs surface. In vitro PTX 
release from polyester-based NPs usually present biphasic profile or very fast complete 
drug release. PHA (Poly Hydroxyalkanotes) and poly ε-CPL for example, released over 50% 
of PTX in the first hours 22,32. On the other hand PDLLA/PLGA PEG NPs exhibited a lower 
burst effect, but nevertheless the total cargo is released in 2 and 4 days, respectively 32,33, 
which, generally, is too fast to meet therapeutic needs. As discussed in the previous 
Chapter with PTX-NPs, when higher drug loading (e.g. 10, 15%) same trend but a slower 
release was achieved. The higher PTX content (w/w) in the polymeric matrix bestow on 
NPs greater hydrophobic character, leading to slower release that is proportional to NPs 
Chapter III – NPs’ Peptide Functionalization and In Vitro evaluation of dual-targeting effect 
87 
 
co-polymer matrix degradation and depending on the total cargo, allows PTX to be 
released in a modulated and controlled way. This may be explained assuming that PTX 
acts as a binding agent, thus higher PTX weight content in the matrix material makes the 
NPs possess greater hydrophobic character, leading to limited water entry into the NPs 
core.  
 
Scheme 3.3 Fabrication of peptide-functionalized-NPs encapsulating PTX via co-precipitation 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.8 Characterization of peptide-functionalized-PTX-NPs. NPs size distribution determined by (A) DLS 
and (B) NTA; (C) TEM images of peptide-functionalized-PTX-NPs with different magnifications; (D) NTA 
sample video frame of NPs moving under Brownian motion in (left) scattering and (right) fluorescent mode 
C 
D 
A B 
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Figure 3.9 In vitro release kinetics of PTX from peptide-functionalized-PTX-NPs at 3 % w/w theoretical drug 
content (PBS 0.1 M with 0.3 % v/v Tween-80, pH 7.4, 37ºC) Mean ± SD (n=3) 
 
Peptide-conjugation efficiency  
AGBBB015F (15F), introduced in 2007 by Demeule and co-workers 34, is a peptide that 
belongs to a family of peptides named Angiopeps , which were derived from the Kunitz 
domain of aprotinin. Angiopeps are known to be able to pass through the BBB with a 
mechanism involving the LDLR (low density lipoprotein receptor).  
Regulon (REG) peptide is able to cross the BBB but its mechanism of action has not been 
reported yet and no relationship between Regulon and the LDLR has been published. It is 
made up of 59 AAs and the proposed structure, predicted with an ab-initio method 35–37, 
can be divided into two parts: (i) a long unstructured flexible chain, (ii) a rigid β-hairpin 
structure, localized near the C-terminal region. The β-hairpin is constituted of 2 beta-
strands and a U-turn, localized in the TVIHG, EVTLH and KR regions, respectively. It is 
supposed that REG interacts with the LA domain of LDLR family using its hairpin region but 
this interaction is insufficient to justify the binding of the whole REG peptide. This 
hypothesis is based on the interacting surface area, which is rather small with respect to 
the total REG surface. Considering REG as a double domain binder, the flexible loop of REG 
should participate in the binding through the residues R13, R19 and K20, K22. Indeed, it 
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has a larger interacting surface and moreover, it has a residue composition and 
configuration that can resemble the flexible Kunitz domain of 15F peptide. In both 
domains the presence of arginine and lysine amino acids ensures the hydrogen bond 
interactions with the LRP1 receptor  
Sulfhydryl groups are useful for peptide conjugation. First, sulfhydryls are not as 
numerous as primary amines; thus, crosslinking via sulfhydryl groups is more selective and 
precise. Second, sulfhydryl groups in proteins are often involved in disulfide bonds, so 
crosslinking at these sites typically does not significantly modify the underlying peptide 
structure. The coupling procedure between peptides and linker is suitable for 
incorporating relatively large peptide possessing Cys residue at the central region of the 
peptide, as described by G. Mezö et al 38. The presence of Reg-peptide on the NPs surface 
was qualitatively validated by NTA under fluorescence mode Figure 3.8 D) and was 
confirmed by fluorometric assay, with a conjugation efficiency of 16.9 ± 2.1 and 15 ± 1.8 % 
for 15F and REG peptides respectively, and by amino acids quantification in 
REG-functionalized-NPs. Pro, Val and Phe were quantified at 33 ± 4.5, 16 ± 2 and 25 ± 5 % 
(w/w) of theoretical amino acid feeding, respectively. 
 
3.3.3 Cell experiments 
Hemocompatibility test 
Analyzing microscopic pictures of the whole blood after NPs exposure at 100ul/ml 
concentration, no change in morphology was observed on red blood cells (RBCs), white 
cell (WBCs) and platelets (Figure 3.10). 15F-NPs and 15F-PTX-NPs were not haemolytic. 
This was confirmed by cell counting analysis, which showed no significant changes in the 
number of RBCs, WBCs and platelets at these conditions. Furthermore, the lack of a 
significant activation of the complement system in the presence of the NPs suspension 
indicated no immunogenicity (Figure 3.11). Finally, no relevant activation of coagulation 
by the intrinsic or the extrinsic pathway was detected (Table 3.2) 
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Control PBS non-incubated                          Control PBS incubated 
     
15F-functionalized-PTX-NPs (100 µg/ml) 
 
15F-functionalized-NPs (100 µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Microscopic pictures of the whole blood after 15F-PTX-NPs exposure 
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Figure 3.11 Hemolysis test, blood cell counting and complement activation study 
Table 3.2 Hemostasis control 
Formulation  TCA or aPTT (%) Quick or PT (%) 
15F-NPs (100 µg/ml) >100 89,44 
15F-PTX-NPs (100 µg/ml) >100 91,87 
Positive control + Kaolin 63,11 112,6 
Blood control incubated 100 91,86 
Blood control non incubated 100 90,24 
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Receptor expression in targeted cells  
Different transporters and receptors present at the BBB have been described as playing 
roles in maintaining the integrity of the BBB and brain homeostasis. Among them, the low-
density lipoprotein receptor-related protein (LRP), whose presence had been proved 
extensively on brain capillary endothelial cells 39–41, possess the ability to mediate 
transport of ligands across endothelial cells of the BBB 13–15. The low-density lipoprotein 
receptor-related protein-1 (LRP-1) is a membrane receptor displaying both scavenging and 
signaling functions. The wide variety of extracellular ligands and of cytoplasmic scaffolding 
and signaling proteins interacting with LRP-1 gives it a major role not only in physiological 
processes, such as embryogenesis and development, but also in critical pathological 
situations, including cancer and neurological disorders 42. Qualitative analysis of LRP-1 
expression was carried out by immunofluorescence on BBMVECs and U-87 MG cells with a 
specific antibody against LRP-1. The results showed high LRP-1 expression in BBMVECs and 
U-87 MG cells (Figure 3.12). 
 
Cellular uptake of peptide functionalized-NPs 
In order to assess the ability of REG-functionalized-NPs to penetrate cells in an energy-
dependent manner, fluorescently-labeled peptides-functionalized-NPs were incubated 
with BBMVECs and U-87 MG cells for 30 minutes at 4ºC and 37ºC and analyzed by 
fluorescent microscopy. As shown in Figure 3.13, while intracellular uptake of 
REG-functionalized-NP was observed at 37ºC in both BBMVECs and U-87 MG cultures, no 
cytoplasmic signal was detected when the incubation took place at 4ºC, suggesting that 
the intracellular transport of the NPs was energy-dependent. In order to confirm that this 
active transport was specifically mediated by the LRP-1 receptor, we studied the cellular 
uptake of REG-functionalized-NPs together with LRP-1 expression in U87 MG cells. After a 
30 minutes incubation, a clear co-localization of LRP-1 receptor (in green) and REG-
peptide-functionalized-NPs (in red) was detected inside the cytoplasm of U-87 MG cells 
(Figure 3.14). This result suggested again that the REG-peptide-functionalized-NPs 
internalization was being mediated by the LRP-1 receptor. 
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Figure 3.12 LRP-1 expression in (A) BBMVECs and (B) U-87 MG detected by a specific secondary antibody 
(Alexa Fluor 488 goat anti rabbit). Cell nuclei were counterstained with DAPI 
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Figure 3.13 Cellular uptake of peptide functionalized NPs.BBMVECs incubated for 30 min in the presence of 
REG-functionalized-NPs at (A) 4 ºC and (B) 37ºC. U-87 MG incubated for 30 min in the presence of REG-
functionalized-NPs at (C) 4ºC and (D) 37ºC. Cell nuclei counterstained with DAPI 
A B 
C D 
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Figure 3.14 Intracellular uptake of REG-functionalized-NPs, 30 minutes transcytosis across the U-87 MG cells 
was performed for REG-NPs. (A) Cell nuclei counterstained with DAPI. (B) LRP1 in U-87 MG cells was labeled 
in green using a primary antibody (rabbit anti-LRP1) and secundary antibody (Alexa Fluor 488 goat anti-
rabbit). (C) Incorporated REG-peptide-functionalized-NPs (in red) detected in vesicular structure of the U-87  
MG cells. (D) Co-localization of REG-NPs (red) and LRP1 (green) is represented in orange in the merged 
image. (E) Image in the white square was enlarged and co-localization of REG-NPs with LRP1 (in orange) is 
indicated by arrow. 
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NPs toxicity study on different cell lines  
 
 MTS on glioma cell line (U-87 MG)  
The in vitro anti-proliferative effect of REG-PTX-NPs, PTX-NPs, REG-NPs (without PTX) and 
free PTX on U-87 MG cells was evaluated using MTS assay. The synthetized block co-
polymers (P, 2P) biocompatibility was confirmed since the drug-free REG-NPs showed no 
decrease in cellular viability and the REG peptide linked on the particle surface did not 
cause obvious cytotoxicity to U-87 MG cells. Cells were incubated with REG-(3%)-PTX-NPs 
and (3%)-PTX-NPs at 20 nM PTX concentrations. This concentration was selected because 
it corresponds to IC50 value for U87-MG cells. As can be seen in Figure 3.15, a marked 
reduction in survival rate (down to 45%) was observed when U-87 MG cells were 
incubated for 8 days with REG-(3%)-PTX-NPs at 20 nM. After the same incubation time, 
PTX showed similar toxicity levels, indicating that the developed REG-PTX-NPs system did 
not decrease the PTX antitumoral activity and that the cytotoxicity against U-87 MG cells 
was in time-dependent manner. Otherwise, for (3%) PTX-NPs a slighter effect was 
observed, with 60 % survival rate showing that the antiproliferative effect of the PTX-NPs 
was markedly elevated by functionalizing with REG peptide. This result suggested that the 
enhanced toxicity in U-87 MG cells might be due to the active cellular uptake mediated by 
LRP1 interaction which increased the intracellular concentration of PTX. 
 
Figure 3.15 Cell viability on U-87 MG incubated with PTX, REG-(3%)PTX-NPs, (3%)PTX-NPs and REG-NPs (drug 
free) at 20 nM PTX concentration after 8 days cell culture (n=3) 
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 MTT on BBMVECs, human neuroblastoma cell line and rat glial cells 
The in vitro toxicity of NPs, 15F-NPs and REG-NPs on BBMVECs, human neuroblastoma cell 
line and rat glial cells was evaluated by using MTS assay. In Table 3.3 are shown the values 
of IC20, IC50 and IC80 which represents the concentrations for each formulation of NPs 
needed to inhibit 20, 50 and 80 % the cellular viability, respectively. Since pronounced 
lower concentrations inhibition of all NPs formulations in respect to SDS, it can be 
assessed that NPs at concentration tested did not cause obvious cytotoxicity to all cell 
lines tested. 
 
Table 3.3 NPs, 15F-NPs and REG-NPs Inhibitory concentration (20, 50 and 80 %) on Astrocytes, BBMVECs and 
IMR-32 cells 
 
 
 
 
 
 
 
 
Astrocytes NPs Reg-NPs 15F-NPs SDS 
IC20 900,1482 µg/mL 500,392 µg/mL 1345,63 µg/mL 103,97078 µg/mL 
IC50 5621,65 µg/mL 2091,47 µg/mL 2924,93 µg/mL 133,058 µg/mL 
IC80 1,10E+08 µg/mL 8741,62 µg/mL 6357,76 µg/mL 170,311333 µg/mL 
         
BBMVECs NPs Reg-NPs 15F-NPs SDS 
IC20 486,013 µg/mL 409,897 µg/mL 215,817 µg/mL 228,530488 µg/mL 
IC50 2211,2 µg/mL 1710439 µg/mL 1988,97 µg/mL 282,165667 µg/mL 
IC80 13682,5 µg/mL 7,10E+09 µg/mL 18330,3 µg/mL 348,548333 µg/mL 
         
         
IMR-32 NPs Reg-NPs 15F-NPs SDS 
IC20 706,689 µg/mL 495,317 µg/mL 671,587 µg/mL 49,3800434 µg/mL 
IC50 1244,77 µg/mL 1036,50 µg/mL 1137,77 µg/mL 84,9392667 µg/mL 
IC80 2213,71 µg/mL 1770,65 µg/mL 1927,57 µg/mL 165,0313 µg/mL 
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 ROS test on BBMVECs, human neuroblastoma cell line and rat glial 
cells 
The Generation of reactive oxygen species (ROS) in vitro was evaluated employing the 
fluorescent probe DCFH-DA that once into the cells, following enzymatic or base-catalyzed 
cleavage of the diacetate groups, it is readily oxidized to the highly fluorescent product 
dichlorofluorescein (DCF) and analyzed by flow cytometry. As shown in Figure 3.16 no 
significant differences in generation of ROS, compared with negative control (glial cells: 
12,11 ± 2,93%; BBMVECs: 16,94 ± 1,24 %; IMR32: 18,86 ± 5,57 %), were detected for the 
three NPs formulations at tested concentration. Otherwise a pronounced and statistically 
significant (p<0.005) percentage increase of cells positive to the production of superoxide 
radical was found for positive control of doxorubicin. 
Figure 3.16 ROS generation in (A) IMR32, (B) 
astrocytes and (C) BBMVECs when exposed to 0,25 
and 0,5 mg/ml NPs, 15F-NPs and REG-NPs 
concentrations, or to doxorubicin  (n=18) 
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 Annexin A5 affinity assay on BBMVECs, human neuroblastoma cell 
line and rat glial cells 
Cell Apoptosis in the different cell lines was evaluated by annexin V y propidium iodide. 
The results of flow cytometry are shown in Table 3.4 with the percentages of cells positive 
to annexin v and PI after treatments with different NPs forumlations at 0.25 and 0.5 
mg/ml concentrations or positive control, doxorubicin, at concentration of 0.3 µg/ml.  As 
can be seen, none of NPs formulations, compared with control, produced a significant 
increase in percentage of cells positive to annexin v or PI. Otherwise, a pronounced and 
statistically significant (p<0.005) percentage increase of cells positive to anexina V and IP 
was observed for doxorubicin.  
 Table 3.4 Cell Apoptosis in the different cell lines when exposed to 0,25 and 0,5 mg/ml NPs, 15F-NPs and 
REG-NPs concentrations, or to doxorubicin, evaluated by annexin V and propidium iodide 
Astrocytes 
Control 0,25 mg/ml 0,5 mg/ml doxo 
Anexina V IP Anexina V IP Anexina V IP Annexin V PI 
NPs 
14,94 ± 
0,88 
12,77 ± 
3,58 
12,85 ± 
7,10 
14,57 ± 
2,53 
12,54 ± 
3,84 
17,82 ± 
3,34     
REG-NPs 
4,55 ± 
0,76 
10,05 ± 
4,56 
4,95 ± 
2,12 
17,00 ± 
6,26 
4,46 ± 
0,70 
15,93 ± 
4,98 
29.99 ± 
4.99* 
42.45 ± 
4,24* 
15F-NPs  
6,59 ± 
1,78 
12,77 ± 
3,58 
7,30 ± 
2,91 
15,33 ± 
3,09 
3,69 ± 
0,53 
12,36 ± 
3,61     
         
BBMVECs 
Control 0,25 mg/ml 0,5 mg/ml doxo 
Anexina V IP Anexina V IP Anexina V IP Annexin V PI 
NPs 
8,11 ± 
3,51 
10,16 ± 
1,46 
10,12 ± 
2,55 
11,38 ± 
3,57 
12,30 ± 
1,80 
10,11 ± 
2,29     
REG-NPs 
5,92 ± 
3,35 
12,37 ± 
6,48 
10,06 ± 
1,86 
9,19 ± 
1,93 
8,87 ± 
3,70 
15,50 ± 
2,54 
28,62 ± 
2,43* 
31,22 ± 
4,27* 
15F-NPs  
7,45 ± 
1,53 
11,68 ± 
1,96 
10,47 ± 
3,44 
8,12 ± 
1,90 
10,22 ± 
2,20 
7,29 ± 
1,10     
         
IMR-32 
Control 0,25 mg/ml 0,5 mg/ml doxo 
Anexina V IP Anexina V IP Anexina V IP Annexin V PI 
NPs 8,84 ±1,61 
12,90 ± 
2,47 
5,86 ± 
1,65 
8,01 ± 
2,53 8,74 ±3,15 
10,68 ± 
4,70     
REG-NPs 
11,94 ± 
1,39 
13,82 ± 
1,45 
12,78 ± 
4,05 
14,35 ± 
2,90 
10,03 ± 
4,51 
15,97 ± 
2,63 
19,90 ± 
2,28* 
58,50 ± 
4,03* 
15F-NPs  
12,24 ± 
0,97 
11,67 ± 
1,78 
13,88 ± 
3,87 
11,90 ± 
1,81 
14,77 ± 
3,27 
11,88 ± 
2,89     
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In vitro blood-brain barrier transportation of PTX-peptide-functionalized 
NPs  
The BBB is localized at the interface between blood and cerebral tissue 43, formed by the 
brain capillary endothelial cells (BCECs), basal lamina, glial cells, perithelial cells and so on. 
Among that, BCECs is the most important component to maintain the function of BBB 
because BCECs differed from other endothelial cells by (i) the absence of fenestration 
correlating with the presence of intracellular tight junctions, (ii) the low level of non-
specific transcytosis and intracellular diffusion of hydrophilic compounds and (iii) the 
polarized expression of membrane receptors and transporters which are responsible for 
the active transport 44,45.  
 Transendothelial transport experiments by NTA and UPLC 
BBMVECs were chosen as an easy BBB model to study the brain delivery property of 
peptide-functionalized-PTX-NPs in vitro. To improve the barrier properties of BBMVECs 
cultures a co-culture of endothelial cells with primary astrocytes isolated from neonatal 
rats was developed. This approach has been shown significantly increasing 
transendothelial electrical resistance (TEER) value 46.  In order to assess the barrier 
integrity, BBB models were characterized in terms of trans-endothelial electrical 
resistance (TEER) and permeability (Pe) of the water-soluble molecular tracer Lucifer 
Yellow (LY). The obtained TEER values were higher than 200 Ωcm2, the measurements 
were performed after 72 hours from the co-culture establishment in 20 Transwells from 
each model. In order to further assess the quality of the established in vitro BBB models, 
BBMVECs permeability coefficient (Pe) to LY was determined for each culturing condition. 
As expected, the presence of glial cells in the model resulted in low LY Pe values (< 0.8 
cm·min-1).  The transport of peptide-functionalized-NPs from the luminal to the abluminal 
compartment was analyzed. REG-PTX-NPs and PTX-NPs were incubated in the luminal 
compartment of the BBB model for 60 minutes at 37ºC and with 5% of CO2. An insert 
without cells, incubating PTX-NPs in the luminal compartment was used as blank. 
Collected samples from the upper and the lower compartment, were analyzed by NTA and 
UPLC. As shown in Figure 3.17, REG-PTX-NPs in the luminal and abluminal compartments 
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reached the equilibrium of concentration. The same result was observed for PTX-NPs in 
both compartments of the insert without cells (blank). In contrast, PTX-NPs passage was 
restricted by the barrier indicating that the presence of REG-based decoration on the NPs 
surface increased the passage across the co-culture in vitro BBB model. 
 
Figure 3.17 REG-PTX-NPs transport across co-culture in vitro BBB model quantified by NTA and UPLC (n=2) 
 
 Transendothelial transport experiments by fluorometric detection 
To study NPs toxicity and transendothelial transport efficiency on BBB in vitro models, 
fluorescently and peptide functionalized NPs at 0.25 and 0.5 mg/ml concentrations were 
employed. The integrity of both barrier models (bend3 and endothelial cells) was 
characterized by analyzing the permeability of the LY coincubated 1 hour with NPs 
solutions. As shown in Figure 3.18, all NPs formulations at both concentrations tested did 
not alter endothelial- and bend3-based barrier integrity since the permeability coefficient 
of LY was equivalent to that of the control cells. 
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Figure 3.18 Integrity of the BBB model with (A) bend3 and (B) endothelial cells after 1 hour incubation with 
NPs, REG-NPs and 15F-NPs formulation at 0,5 and 0,25 mg/ml concentrations (n=9) 
 
By a fluorometric quantitative study analyzing fluorescence emitted by AlexaFluor 568 
labeled NPs, the transport of peptide-functionalized-NPs from the luminal to the 
abluminal compartment was analyzed. As shown in Figure 3.19 referred to bend3 BBB 
model, REG-NPs showed a not significant increase in permeability (0,5 mg/ml: 0,12 ± 0,01 
x10-3 cm/min; 0,25 mg/ml: 0,13 ± 0,03 x10-3 cm/min) in comparison with NPs (0,5 mg/ml: 
0,11 ± 0,01 x10-3 cm/min; 0,25 mg/ml: 0,10 ± 0.02 x10-3 cm/min). Otherwise, for 15F-NPs 
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an intensely increased permeability (p<005) due to the efficient peptide-functionalization 
was obtained (0,5 mg/ml: 0,22 ±  0,02 x10-3 cm/min; 0,25 mg/ml: 0,22 ±  0,01 x10-3 
cm/min). With the endothelial BBB model it was observed again, an insignificant increase 
in REG-NPs permeability against a considerable higher transendothelial transport 
capability increase (p<0,005) of 15F-NPs. 
 
 
 
Figure 3.19 Permeability coefficient of NPs, REG-NPs and 15F-NPs across (A) bend3 and (B) endothelial 
culture in vitro BBB model quantified by fluorimetry (n=9) 
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3.4 Concluding Remarks 
We have employed peptides (15F, REG) known to be efficiently transported across the 
BBB as a targeting moiety to develop a dual-targeting drug delivery system. A novel 
biodegradable block co-polymer (2P) has been successfully synthetized to obtain in only 
one step via modified nanoprecipitacion emulsifier-free, a very monodisperse 
peptide-PTX-NPs population, spherical in shape, with particle size of ~180 nm, 
polydispersity of ~0.1 and with a surrounding PEG corona on the surface. High drug 
loading, probably due to strong lipophilic interactions of PTX with hydrophobic inner 
region of NPs, has been obtained and in vitro PTX release from NPs has exhibited an 
approximately first-order profile, with a controlled release depending on the total cargo, 
for a prolonged period of time. In vitro studies have confirmed a pronounced cellular 
uptake of peptide functionalized-PTX-NPs by U-87 MG and BBMVECs cells. Dual-targeting 
effect has been demonstrated not only by a significant increased transendothelial 
transport ratio of PTX in an in vitro BBB model but also by enhanced in vitro anti-tumoral 
activity against U-87 MG. Considering these promising results, next chapter (Chapter IV) is 
centered in the in vivo characterization of the developed nanocarriers. Relevant in vivo 
properties of the NPs are explored to assess their biological profile in view of their 
application as a target anticancer delivery system.   
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4.1 Introduction 
Chapter II and Chapter III have developed a peptide targeted drug delivery system able to 
modulate and control the release of PTX across an in vitro BBB model and specifically, on 
human glioma cells. Since promising in vitro ability to shuttle and deliver PTX over the 
BBB, the NPs system has been translated to in vivo conditions to evaluate biological 
activities, focusing on pharmacokinetics properties (mainly biodistribution), and in 
particular on brain uptake. Effectively, evaluating the in vivo fate of a candidate 
nanocarriers in animals is a necessary step to estimate its potential as a targeted drug 
delivery agent.  
Nanocarriers designed for the selective delivery of drugs to specific tissues or organs after 
systemic administration require a long circulation times in the bloodstream, in order to 
reach the targeted organ or tissue before clearance or degradation occurs 1–4. This is not 
likely to happen if the carrier is taken up by RES organs (liver, spleen and bone marrow) 
immediately after intravenous administration or if rapid renal excretion occurs. Similar 
considerations are needed for nanostructure meant to be a circulating reservoir for 
sustained release of therapeutic cargoes. Hence, investigation of the pharmacokinetic 
properties of NPs for controlled release is of paramount importance. 
Different approaches can be used to investigate the pharmacokinetic properties of NPs. 
Visualization methods such as optical or electron microscopies are often employed. 
Microscopy requires fluorescent dyes, loaded into NPs or covalent coupled to particle 
building blocks5,6, to visualize the fluorescence emission in the whole body of a living small 
animal (e.g. NPs uptake in organs)7,8. Next to fluorescence microscopy, electron 
microscopy is commonly used. With this technique, single particles can be visualized (e.g. 
in specific regions of the brain). Although in vivo imaging is a rapidly progressing field, 
detection is at present not sensitive enough to visualize the particles within the 
microenvironment of the brain for example, or to provide quantitative information on the 
usually low concentrations that have accumulated.  
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The first part of this chapter focuses on two radiolabelling strategies for NPs and peptide 
for PET-CT imaging and gamma counting, respectively employing radionuclides positron 
and gamma emitters. As discussed in Chapter III, one important advantage of using NPs as 
a platform for drug delivery is the possibility to incorporate or conjugate multiple agents 
or functional groups. Among them, agents for non-invasive imaging by means of nuclear 
imagine technique represent an ideal tool for investigate in vivo fate of the NPs, including 
stability in biological environments (stealthiness), pharmacokinetics and specific organ 
uptake9.  
 
To quantitatively study the in vivo uptake of candidate nanocarriers at the target site with 
high sensitivity, the particle itself or an entrapped compound can be radiolabeled. Most 
commonly, radioisotopes like 3H, 18F, 14C or 125I are used. Radiolabelling can be performed 
with or without slight modifications of the original NP surface. For ligands to bind 
effectively, each radionuclide can be conjugated directly on the NP surface, with or 
without a spacer, or can be attached to the NPs during chemical synthesis. The spacer 
groups between the NP surface and the radionuclide or the biomolecule can be a simple 
hydrocarbon chain, a peptide sequence or a polyethylene glycol linker 10.  
 
In vivo imaging techniques such as Positron Emission Tomography (PET), Single Photon 
Emission Computerized Tomography (SPECT), Magnetic Resonance Imaging (MRI) or 
Fluorescence Tomography show high sensitivity and tissue penetration and are widely 
used to investigate the in vivo characteristics of NPs. These techniques can be applied 
both to small and large animal species as well as humans and  allow the determination of 
quantitative pharmacokinetics by imaging the uptake of the NPs9. 
It has to be considered how NPs are interacting with tissues and cells, and especially which 
time frame allows a suitable visualization of certain effects and functions. The physical 
half-life (T½) of the radionuclide plays a crucial role for measurements in the desired time 
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frame, and it has to be considered which radionuclide or half-life, respectively, is suitable 
for the investigated question and pharmacokinetic profile (Scheme 4.1).  
 
Scheme 4.1 The Clock-Of-Nuclides showing the positron emitters used for radiolabelling of NPs or peptides11 
 
The 18F positron emitter is a very attractive radionuclide for radiolabelling of NPs due to its 
relatively long half-lived (T1/2 = 109.7 min) and can be produced as [18F]F- in the GBq scale 
in all biomedical cyclotrons. 18F emits a positron from the nucleus traveling only a short 
distance through the tissue before interact with a free electron. The outcome of this 
interaction (Annihilation) produce two antiparallel photons with energy 511 keV, 
independent of their kinetic energy (Scheme 4.2).  
 
Scheme 4.2 Decay of 18F and basic physics of Positron Emission Tomography (PET) Imaging 
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Unfortunately, direct labelling with [18F]F- requires harsh conditions (for example, high 
temperature and water-free organic solvent), and long reaction times;12 alternatively, 
indirect labelling methods can be used. In this chapter, a radiolabeled prosthetic group is 
prepared in a first step, purified, and subsequently coupled to the molecule of interest, 
usually under mild conditions.  
 
 
 
Alternatively, radioactive iodine is another useful tool for labelling of various large and 
small molecules. Many radioiodination methods, including electrophilic radio-iodination 
with various oxidants, and isotopic exchange with or without catalyst, have been well 
established for small organic molecules13. Radioiodination techniques include a variety of 
electropositive iodine sources, such as molecular iodine, iodine monochloride, NaI or KI 
with chloramine-T or iodogen, electrolytic methods, and enzymatic methods. Many 
different substances can be labeled by radioiodination. In most of studies with labeled 
molecules, it is necessary to measure very low concentrations of the substance under 
investigation, which in turn requires the preparation of high specific radioactivity labeled 
species. Two radioisotopes of iodine are widely available, 125I and 131I. 125I has a half-life of 
nearly 59 days and decays by electron capture to an excited state of 125Te, which decays 
immediately by gamma ray emission with a maximum energy of 35.5 keV (Scheme 4.3). 
131I has a half-life of 8.02 days and decays 100% by electron emission, also resulting in the 
emission of gamma rays with a maximum energy of 364.5 keV. As γ-emitters, both are 
useful for in vitro and ex vivo applications; the application of 125I in vivo is restricted due to 
the low energy of the gamma rays, which may lead to a significant attenuation, especially 
in large animals or humans.  
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Scheme 4.3 Decay of 125I 
Labelling methods for potential drug delivery systems are an indispensable need to 
provide the radiolabeled analogue and this chapter describes novel strategies and various 
approaches for the radiolabelling of the developed drug delivery systems using positron 
and gamma emitters. 
Pharmacokinetics provides a mathematical basis to assess the time course of NPs and 
their effects in the body. It enables the following processes to be quantified: (i) absorption 
(ii) distribution (iii) metabolism, (iv) excretion. These pharmacokinetic processes 
determine the NPs concentration in the body and a fundamental understanding of these 
parameters is required to design an appropriate drug delivery system. Ideally, the 
concentration of NPs should be measured at the site of action of the drug, that is, at the 
receptor. However, concentrations are normally measured in whole blood from which 
serum or plasma is generated.  A variety of techniques is available for representing the 
pharmacokinetics of a compound or NP. The most usual is to view the body as consisting 
of compartments between which candidate nanocarriers moves and from which 
elimination occurs. The transfer of compound between these compartments is 
represented by rate constants.  
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In this chapter a pharmacokinetic study is carried out to study the influx of the 
radiolabeled and peptides functionalized NPs across the BBB after single iv bolus injection. 
Multiple-time regression analysis is adapted to assess the fraction of the administered 
dose that is distributed within the BBB complex or is excreted from the body, based on a 
two-compartment mathematical model proposed by Patlak, Blasberg, and 
Fenstermacher14,15. The unidirectional influx constant (Ki) of NPs formulations is calculated 
and compared with known crossing compounds. Along with pharmacokinetic parameters, 
biodistribution studies are also used as a quantitative method to study in vivo NPs brain 
uptake.   
 
For γ emitting-based biodistribution studies, the nanoparticles are usually administered 
intravenously16. After administration, the animals are sacrificed at a specific time point, or 
preferably at several time points. The brain is taken out, along with some of the major 
organs where the particles are likely to end up, including liver and kidney. If a γ-emitting 
label is used, organs can be directly counted in a γ counter. The amount of compound 
found in the brain and other organs can be represented as mass/organ or mass/gram. In 
this way, the increase in brain uptake compared to the control sample is obtained. Along 
with the experimental samples, the injection sample, as it was administered to the 
animals, can be assayed for NPs using the same analytical method, so that the amount of 
NPs taken up into the brain can be expressed as a percentage of the injected dose (%ID).  
 
As a result, this chapter seeks to explore new radiolabelling strategies by synthetizing and 
purifying optimized NPs, labeled with radionuclide gamma or positron emitters, to 
investigate their pharmacokinetics in vivo behaviour and biodistribution by PET and 
gamma counter. A special attention is given to the NPs uptake into the brain by using a 
theoretical model of blood-brain exchange in order to evaluate the potential of the 
peptide functionalized NPs as brain targeting drug delivery system. 
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4.2 Experimental Section  
The experimental part of this work has been carried out in the Molecular and Functional 
Imaging Facility of CIC biomaGUNE.  
4.2.1 Materials 
1.8-Octanediol (98%), 2,2′-Dithiodipyridine (≥97%) and polyethyleneglycol (PEG, Mw 1.5 
KDa) were purchased from Sigma (Sigma–Aldrich, USA). Glutaric acid (99%) was obtained 
from Alfa Aesar (USA). AGBBB015F (CGGKTFFYGGSRGKRNNFKTEEY) and Regulon 
(HKKWQFNSPFVPRADEPARKGKV HIPFPLDNITRVPMAREPTVIHGKREVTLHLHPDH) peptides 
fluorescently labeled with carboxyfluorescein and 5-Tamra, respectively, were synthesized 
by Innovagen AB (Sweden). PEG Thiol acids, α-Thio-ω-carboxy poly (ethylene glycol) (MW 
458 and 3.000 Da) were supplied by Iris Biotech GmbH (Germany). PTX (≥ 97%) was 
provided by Yunnan Hande Bio-Tech CO, LTD, P.R. China. Iodination beads and Bolton-
Hunter reagents were purchased from Thermo Scientific Pierce. All other chemicals were 
of analytical grade and were purchased from Sigma (Sigma–Aldrich, Germany). 
 
4.2.2 Synthesis and characterization of [18F]-labeled/peptide-
functionalized NPs 
Synthesis of 18F-labeled active agent 18F-[FBBA] 
 
The prosthetic group 4-[18F]fluorobenzyl-2-bromoacetamide ([18F]FBBA, [18F]4, Scheme 
4.4) was synthesized following a previously reported methodology with minor 
modifications. 4-[18F]fluorobenzonitrile ([18F]2) was prepared by reaction of 4-Cyano-
N,N,N-trimethylanilinium trifluoromethanesulfonate (1) with [18F]F- generated by proton 
irradiation of [18O]H2O; [18F]F- was first trapped in an anion exchange resin and 
subsequently eluted with K2CO3/H2O and Kryptofix2.2.2/MeCN. After azeotropic 
evaporation of the solvent, the dried potassium [18F]fluoride-Kryptofix2.2.2 complex was 
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dissolved in dry DMSO and the resulting solution was reacted with 1 (130ºC, 10 min). The 
reaction mixture containing [18F]2 was cooled, the reaction crude was diluted with purified 
water (9 mL) and the mixture was flushed through a C-18 cartridge (Sep-Pak®, Waters). 
The retained labelled species was eluted with 1.5 mL of THF, dried over Na2SO4 and 
molecular sieve and reacted with LiAlH4 in THF (120ºC, 2 min) to yield [18F]3, which was 
further reacted with bromoacetyl bromide (solution in CH2Cl2). After addition of 2 mL of 
MeCN/water 1/1, the mixture was purified by high performance liquid chromatography 
(HPLC) using a VP125/10 Nucleosil 100-7C18 semipreparative column (Macherey-Nagel) as 
stationary phase and MeCN/water 1/1 as the mobile phase (retention time = 13 min) to 
yield [18F]4 in overall yield of 12% (decay corrected). The presence of the desired product 
was confirmed by HPLC and co-elution with reference standard, using an Agilent 1200 
Series HPLC system with a multiple wavelength UV detector (λ = 254 nm) and a 
radiometric detector (Raytest). A RP-C18 column (Eclipse XDB C18, 4.6x150 mm, 5 μm 
particle size) was used as stationary phase. The elution solutions were A (water) and B 
(MeCN). The column was eluted with a gradient: t=0 min, 95% A, 5% B; t=0.5 min, 95% A, 
5% B; t=7.5 min, 1% A, 99% B; t=10min, 1% A, 99% B, and the flow was 1 mL/min 
(retention time = 9.5 min, injected volume = 20 µL). The collected fraction was used 
without further treatment for subsequent labelling steps. 
 
Scheme 4.4 Reaction for the preparation of [18F]FBBA ([18F]4); (i) azeotropically dried [18F]F-, K2CO3, K2.2.2., 
MeCN, 130°C, 10 min; (ii) 0.1M LiAlH4, 2 min, 120 °C; (iii) bromoacetyl bromide in CH2Cl2, 2 min, RT 
 
Synthesis of 18F-[FBBA]-PEG-thiol-acids 
Preparation of 18F-labelled PEG-thiol-acids was carried out by condensation of [18F]-FBBA 
with the corresponding α-Thio-ω-carboxy poly (ethylene glycol). These experiments were 
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conducted to have a proof of principle of the feasibility of the condensation reaction. 
Experimentally, a 1 mg/ml solution of PEG-thiol-acid in 1:1 (v/v) phosphate buffer saline 
and acetonitrile (total volume = 250 µl), was mixed with a solution of [18F]-FBBA in 
water/acetonitrile (250 µl). Two different PEG-thiol-acids with molecular weights of 458.6 
and 3300 Da were used, and experimental conditions were optimized (T = 70-90°C, t = 10-
30 min) in both cases. The radiochemical conversion was determined by radio-HPLC, using 
the same experimental conditions as above. For both polymers, the reaction proved to 
run smoothly at 90°C, yielding approximately 90% of radiochemical conversion after 10 
minutes. Lower temperature required longer reaction times and lower radiochemical 
conversion values were achieved. Longer reaction times did not improve conversion. After 
optimization of experimental conditions, large scale syntheses for in vivo experiments 
were carried out using the optimal reaction time (T= 90°C, t = 10 min); the radiolabelled 
species were purified by HPLC under analytical conditions described above using a 500 µL 
injection loop. The fractions containing the pure labelled polymers were collected, 
allowed to complete decay and the identity of the labelled species was confirmed by 
UPLC/ESI-MS. Analyses were performed using an AQUITY UPLC separation module 
coupled to a LCT TOF Premier XE mass spectrometer (Waters, Manchester, UK). An 
Acquity BEH C18 column (1.7 µm, 5 mm, 2.1 mm) was used as stationary phase. The 
elution buffers were A (water and 0.1% formic acid) and B (Methanol and 0.1% formic 
acid). The column was eluted with a gradient: t=0 min, 95% A, 5% B; t=0.5 min, 95% A, 5% 
B; t=7.5 min, 1% A, 99% B; t=10min, 1% A, 99% B. Total run was 10 min, injection volume 
was 5 µL and the flow rate 300 µL/min. The detection was carried out in negative ion 
mode, monitoring the most abundant isotope peaks from the mass spectra.   
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Synthesis of 18F-[FBBA]-P Block co-polymer ([18F]P) 
The radiosynthesis of 18F-[FBBA]-P Block co-polymer ([18F]P) was approached for the 
subsequent preparation of 18F-labeled NPs. Experimentally, a 1 mg/ml solution of P in 1:1 
(v/v) phosphate buffer saline and acetonitrile (total volume = 250 µL), was mixed with an 
equal volume of a solution of [18F] FBBA in water/acetonitrile. The reaction was incubated 
at a pre-determined temperature and the radiochemical conversion was monitored at 
different times from chromatographic profiles (conditions described above). Different 
incubation times (30, 60, 90 and 120 min) and temperatures (90° and 120°C) were tested 
in order to achieve optimal conditions.  
Large scale syntheses for in vivo experiments were carried out using the optimal reaction 
time (30 min) and temperature (90°C); the radiolabelled species were purified by HPLC 
under conditions described above, using a 500 µl injection loop. 
  
 
Synthesis and [18F]-labelling of 3P block co-polymer ([18F]3P) 
The second strategy for the preparation of radiolabelling NPs required the preparation of 
a novel block co-polymer (3P) labeled with 18F. First, the microwave-assisted production of 
a pre-polymer was approached by reacting glutaric acid and 1.8-octanediol at a feeding 
molar ratio of 1:1.2 at 100 W for 1 hour. The reaction was performed under vacuum with 
continuous stirring and air-cooling to maintain the temperature at 120º C. The resulting 
pre-polymer, which contained an excess of 1.8-octanediol, was reacted with the PEG-thiol-
acid (3.3 KDa) to obtain 3P block co-polymer. This second reaction was conducted in a 
microwave reactor under experimental conditions described above, using a ratio 1:1 
(w/w) between pre-polymer and PEG-thiol-acid. Finally, radiolabelling of the 3P was 
achieved by condensation with 18F-[FBBA]  under the same experimental conditions used 
for the preparation of 18F-labelled PEG-thiol-acids.  
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Synthesis and characterization of [18F]-labeled/peptide-functionalized-NPs 
The synthesis of 18F-labelled/peptide functionalized NPs was approached by modifying the 
nano co-precipitation method described in Chapter III. Three different strategies were 
followed, depending on the labelled species used. The first strategy (Scheme 4.5 A) 
consisted of dissolve block co-polymers 18F-P and 2P at ratio 9:1 (w/w) in 1 ml of acetone 
to form the diffusing phase.  This phase was then added to 20 ml of milliQ water, by 
means of a syringe, controlled by a syringe pump (KD Scientific) under magnetic stirring at 
room temperature; the needle was positioned directly in the medium and a flow rate of 
50 µl/min was used. The resulting suspension was allowed to stir uncovered, in order to 
allow the evaporation of acetone. The suspension was purified by centrifugation (Hettich 
Centrifuge, EBA 21, 4000 g, 45 min at RT) with ultracentrifugal devices (Amicon Ultra-15, 
Ultracel membrane with 100,000 MWCO, Millipore, USA). The second strategy consisted 
of dissolving block co-polymers P, 2P and [18F]3P in the organic phase (acetone) at ratio 
8:1:1 (w/w)  (Scheme 4.5 B), and following exactly the same experimental procedure. 
Finally, and taking advantage of the hydrophobicity character of the labelled prosthetic 
group, a third strategy consisting of encapsulating 18F-[FBBA] into the peptide-
functionalized NPs was approached (Scheme 4.5 C). With that aim, the labelled species 
([18F]FBBA) was dissolved in the organic phase (acetone, 1 ml) together with the starting 
polymers, and the solution was added dropwise to the aqueous phase under continuous 
stirring. 
In all cases, the physiochemical properties (size and zeta potential) of the resulting 18F-
labeled/peptide-functionalized NPs were determined after complete decay as described in 
Chapter III. To assess radiolabelling efficiency (R.E., %), the amount of radioactivity in the 
pellet and supernatant after centrifugation were determined, and R.E. was calculated 
using Equation 4.1 
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Equation 4.1 
 
 
Scheme 4.5 Three strategies for the fabrication of 18F-labeled and peptide-functionalized-NPs via co-
precipitation. Labeled parte are (A) block co-polymer P, (B) block co-polymer 3P and (C) [18F]FBBA 
To assess the radiochemical stability, NPs were prepared and purified as described above 
and subsequently resuspended in 200 µL of physiologic NaCl 0.9% solution (Braun Medical 
S.A.). The suspension was then divided into 4 different aliquots containing 50 µL of the 
NPs each. The aliquots were kept at 37°C for 1, 3, 24 and 48 hours, respectively. The 
samples were then filtered and radioactivity was measured in a 2470 WIZARD2 Automate 
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Gamma Counter (PerkinElmer). The dissociation of 18F (expressed in percentage) at each 
time point was calculated as the ratio between the amount of radioactivity in the filtrate 
and the starting amount of radioactivity. 
 
4.2.3 Synthesis and characterization of [125I]-labeled/peptide-
functionalized NPs  
Iodination of 15F, REG peptides and characterization 
Labelling with Iodine-125 involves incorporation of Iodine-125 into tyrosine residues 
within the peptide. 15F peptide was radiolabeled with standard procedure using iodo-
beads. Briefly, beads (2 per iodination) were washed twice with 1 ml of PBS on a 
Whatman filter and resuspended in 60 µl of PBS (0.1 M pH 6.5). Na [125I]I (approximately 1 
MBq) was added to the beads suspension for 5 minutes at room temperature. Iodination 
of the peptide was initiated by the addition of 100 µl of 15F diluted in PBS at 150 ng/ml. At 
different incubation times (5, 10 15, 20 minutes, RT) the reaction was stopped by 
removing iodo-beads and the radiolabelling efficiency was determined by HPLC, using an 
Agilent 1200 Series HPLC system with a multiple wavelength UV detector (λ = 215 nm) and 
a radiometric detector (Gabi, Raytest). A RP-C18 column (Teknokroma, 18 µm, 15 x 0.46 
mm) was used as stationary phase, and the mobile phase consisted of a gradient of A 
(0.1% TFA/water) and B (0.1% TFA/Acetonitrile); 0 min, 100% A; 30 min, 100% B; flow rate 
= 1 ml/min; retention time = 12.5 min). Large scale syntheses (37 MBq) for in vivo 
experiments were carried out using the optimal reaction time (15 min) and the 
radiolabelled 15F was purified by HPLC under identical conditions.  
For REG-peptide, which lacks accessible tyrosine residues, free amines were derivatised 
with iodinated Bolton-Hunter reagent. Briefly, 2 µl of Bolton-Hunter reagent solution (0.5 
mg/ml DMSO) were added to labelling buffer (50 mM sodium phosphate buffer, pH 7.5, 
~1 MBq Na 125I). Chloramine-T (1µg/µl in 50 mM sodium phosphate buffer, pH 7.5) was 
immediately added and the mixture was incubated for 15 seconds. 125I-Labeled Bolton-
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Hunter reagent was extracted by adding 5 µl of DMF and 100 µl of benzene; the aqueous 
phase was removed and the organic phase was dried by evaporation under a gentle 
stream of air. REG-peptide solution (150 ng/µl in 60 µl ice-cold 50 mM sodium borate 
buffer) was added to the dried, labeled reagent and after incubation for 2 hours on ice, 
the reaction mixture was analyzed by HPLC, using the same chromatographic system and 
experimental conditions specified above (λ=546, retention time = 12.5 min).  Large scale 
syntheses (37 MBq) for in vivo experiments were carried out using identical experimental 
conditions and the radiolabelled REG-peptide was purified by HPLC under the same 
conditions. The stability of both labeled peptides was determined by HPLC at t=24 hours.    
The radiolabelling of peptide-functionalized-2P block co-polymers was approached 
following the same protocols described above; iodination of the peptides was initiated by 
adding 200 µl of 2P block co-polymer at 5 mg/ml concentration in PBS and in sodium 
borate buffer for 15F-2P and REG-2P, respectively.  
Synthesis and characterization [125I]-labeled and peptide-functionalized-NPs 
Following the nano co-precipitation method developed in Chapter III and employing 
radiolabeled 2P block co-polymers, 125I-15F- and 125I -REG-functionalized NPs were 
obtained for in vivo experiments. Obtained 125I-labeled-NPs were physiochemical 
characterized, in terms of size and zeta potential, after complete decay, as described in 
Chapter III. Activity of the NPs pellet, after centrifugation, was measured before animal 
injection. 
4.2.4 In vivo and ex vivo experiments  
Healthy, 9-10 weeks aged Sprague-Dawley rats (Harlan, Udine, Italy) were used to 
examine the biodistribution pattern of radiolabelled and peptide-functionalized-NPs after 
intravenous injection. The animals were maintained and handled in accordance with the 
Guidelines for Accommodation and Care of Animals (European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes) 
and internal guidelines, and experimental procedures were approved by the Ethical 
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Committee and local authorities. Rats were acclimated to the housing facility at 25°C and 
55% of humidity under light/dark conditions for at least 5 days prior to experiments.  
 
 
In vivo biodistribution in rats (PET-CT Imaging)   
Animals were anesthetized with 4.5% isoflurane in pure oxygen as carrier gas. 18F-peptide-
functionalized-NPs were suspended in a certain volume of saline solution (NaCl 0.9%) to 
obtain the required concentration of radioactivity (37-74 MBq/ml) and intravenously 
administered via one of the lateral tail veins. Formulations of 18F-3P and 18F-FBBA were 
also administered and used as controls.  
PET-CT imaging was performed on an eXplore Vista-CT camera (GE Healthcare). 
Acquisition of the scans was started immediately after dose administration. Three beds 
were defined to acquire whole body images (frames: 2 x 2 min, 3 x 5 min, 2 x 10 min, total 
acquisition time = 117 min). After acquisition, a CT scan was performed for a later 
attenuation correction application in the image reconstruction.  Random and scatter 
corrections were also applied to the reconstructed images (2DOSEM iterative algorithm, 4 
iterations). PET-CT images were co-registered and analyzed using PMOD image processing 
tool. Volumes of interest (VOIs) were drawn in the kidneys, liver, stomach and brain, using 
the CT images for anatomical reference. Time–activity curves (decay corrected) were 
obtained for each organ as cps/cm3. Curves were transformed into real activity (Bq/cm3) 
curves by using a calibration factor. Injected dose and organ mass normalizations were 
finally applied to data. 
Ex vivo Pharmacokinetics and biodistribution in rats (Gamma-counter) 
Healthy, 9-10 weeks aged Sprague-Dawley rats (Harlan, Udine, Italy) were used to 
examine the pharmacokinetics and biodistribution of peptide-functionalized-PTX-NPs. The 
animals were maintained and handled in accordance with the Guidelines for 
Accommodation and Care of Animals (European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other Scientific Purposes) and internal 
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guidelines, and experimental procedures were approved by the Ethical Committee. Rats 
were acclimated to the housing facility at 25ºC and 55% of humidity under light/dark 
conditions for 5 days before experiments. Animals were randomly divided into four groups 
(n=3 per group) and were anesthetized with 4.5% isoflurane in pure oxygen as carrier gas. 
125I-15F, 125I-REG, 125I-15F-PTX-NPs and 125I-REG-PTX-NPs were suspended in a certain 
volume of saline solution (NaCl 0.9%) to obtain the required concentration of radioactivity 
(~1.85 MBq/mL). Peptides and NPs solutions were intravenously administered via one of 
the lateral tail veins. In each group, at pre-defined time points (2, 5 and 10 minutes post 
injection) mice were anesthetized and blood samples (c.a. 100 µl) were withdrawn by 
cardiac puncture. Immediately after, animals were anesthetized by 
exsanguination/perfusion using saline solution and main organs (liver, kidney, brain and 
cerebellum) were harvested, rinsed with PBS solution and stored in plastic vials at -20°C 
until being submitted to gamma counting. Blood samples were introduced into 
heparinized tubes, counted in the gamma counter (2470 Wizard2, PerkinElmer) and then 
submitted to centrifugation to separate the plasma (1000 g, 10 minutes) and stored at -
20ºC until analysis by gamma counting. Measurements in the gamma counter were 
transformed into amount of radioactivity per gram of tissue by using a calibration curve, 
and values were normalized to injected amount of radioactivity to obtain the percentage 
of injected dose per gram of tissue (%ID/g) at each time point.  
Multiple-time regression analysis was used to study the influx of radiolabeled peptides 
and NPs across the BBB. A two-compartment model of the BBB with unidirectional influx 
was used 14,15. The unidirectional influx rate (Ki, expressed in units of microliters per-gram 
minute) and the apparent volume of distribution at time 0 (Vi expressed in units of 
microliters per gram) were determined from the following equation: 
𝐴𝑚/𝐶𝑝𝑡 = 𝐾𝑖 [∫ 𝐶𝑝(𝜏)𝑑𝜏
𝑡
0
] /𝐶𝑝𝑡 + 𝑉𝑖  
Equation 4.2 
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where Am is the concentration of radioactivity in the brain, Cpt is the concentration of 
radioactivity in arterial plasma at time t and exposure time (Expt, expressed in minutes) is 
calculated as the integral of the concentration of radioactivity over time divided by the 
concentration of radioactivity at time t [∫0t Cp(τ)dτ]/Cpt. The slope of the linear region 
when plotting Am/Cpt vs Expt corresponds to Ki. The half-time disappearance and the 
distribution volume were calculated from the slope and the intercept, respectively, of the 
linear region obtained when plotting the log of the %ID/g in serum vs time. Drug clearance 
(CL), defined as the volume of plasma in the vascular compartment cleared of drug per 
unit time by process of metabolism and excretion, is related to half-life by the following 
equation:   
𝐶𝐿 =
ln 2  𝑉𝑖
𝑡1/2
 
Equation 4.3 
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4.3 Results and Discussion 
4.3.1 Synthesis and Characterization of [18F]-labeled NPs 
Characterization of 18F-FBBA and 18F-labeled polymers 
The labelled active agent [18F]-FBBA was synthesized following a well-established 
procedure 17. The presence of the desired labelled species was confirmed by HPLC and 
co-elution with reference standard (Figure 4.1). Radiochemical yields similar to those 
previously reported in the literature (16%, decay corrected; total synthesis time 
approximately 90 min including purification) were achieved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Labelled active agent characterization. HPLC chromatograms of (A) FBBA (reference standard 
solution, UV detector) and (B) [18F]-FBBA (purified fraction, radiometric detector) 
 
The coupling reaction of the PEG-thiol-acids with [18F]-FBBA (Scheme 4.6) was optimized 
by using different temperatures and reaction times. In Figure 4.2, the radiochemical 
conversion values (obtained by direct integration of the radiometric chromatographic 
profiles) at different reaction times are shown (PEG-thiol-acid with MW = 458.6, T = 90°C). 
As it can be seen, similar radiochemical conversion values were obtained for t>10 min. 
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18F-PEG-thiol-acid 
 
This kinetic profile was also observed for T=70°C, although lower conversion values (<85%) 
could be achieved and the plateau was slightly delayed (t>20 min). Very similar results 
were obtained for the higher MW PEG-thiol-acid. Figure 4.3 shows the chromatographic 
profiles (radiometric detector) of the reaction mixture at t=0 min and t=10 min. It can be 
seen that, for the lower MW polymer, the peak corresponding to the radiolabelled 
condensation product appears even at t=0. This is due to the time gap between reaction 
initiation and injection into HPLC (approximately 3 minutes). Thus, the reaction was taking 
place (slowly) at room temperature. After purification under optimal conditions, overall 
radiochemical yields of 51±7% (uncorrected) were achieved. UPLC-ESI/MS analysis of the 
collected fractions confirmed the presence of the condensation products (see for example 
Figure 4.4).  
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Scheme 4.6 Synthesis of [18F]-FBBA-PEG-thiol-acids by the condensation of [18F]FBBA with PEG-thiol-acid of 
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Figure 4.2 Radiochemical conversion of 18F-FBBA into 18F-FBBA-PEG as a function of time; T = 90 °C; 
MW = 458.6 Da 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 HPLC chromatograms obtained during reaction of PEG-thiol-acid low MW and [18F]-FBBA. (A) 
Reaction time = 0 min; and (B) Reaction time = 10 min (T = 90˚C, radiometric detector) 
 
 
 
 
 
 
 
 
Figure 4.4 MS spectrum of [18F]-FBBA-PEG. 
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18F-P block co-
polymer 
A 
(min) (min) 
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Incorporation of the labelled active agent 18F-[FBBA] into block-co polymers P and 3P was 
carried out following the chemical reaction schematized as shown in Scheme 4.7 and 
Scheme 4.8, respectively. Radiochemical conversion value of 52% and 65% were achieved 
for polymer P at 90 and 120°C, respectively (Figure 4.5). However, at 120°C the reaction 
occurred faster, reaching a plateauy after 30 minutes. The plateau was reached only after 
120 min when the reaction was conducted at 90°C. For 3P block co-polymer, 
radiochemical conversion was approximately 60 % after 1 hour (Figure 4.6) when the 
reaction was carried out at 120°C. 
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Scheme 4.7 Synthesis of [18F]-FBBA-P block co-polymer 
 
Figure 4.5 Radiochemical conversion of [18F]-FBBA into [18F]-FBBA-P as a function of time at (A) 90 ºC and (B) 
120ºC 
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Scheme 4.8 Synthesis of [18F]-FBBA-3P block co-polymer: obtained pre-polymer reacted with PEG-thiol-acid 
(Mw 33 KDa) and following condensated with [18F]-FBBA 
 
Figure 4.6 Conversion of [18F]-FBBA into [18F]-FBBA-3P as a function of time  
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Synthesis and characterization of [18F]-labeled NPs 
By modifying the nano co-precipitation method described in chapter III, 18F-labeled and 
peptide-functionalized NPs were obtained following three different methods as specified 
in the experimental section of this chapter. These three strategies resulted in values of 
R.E. ranging from 5 to 14 %, related to the amount of starting radiolabelled polymer 
(strategies 1 and 2) or starting amount of [18F]FBBA (strategy 3) (Table 4.1).   
According to the measurements of particle size and zeta potential, the incorporation of 
the radiolabel did not result in statistically significant alteration of the physic-chemical 
properties of the resulting NPs; all the formulations exhibited average diameters and zeta-
potential values within the required specifications (data not shown).  
Radiochemical stability studies showed no detachment of the radioactivity for NPs 
prepared following strategies 1 and 2 (radiochemical purity > 95% after 48 hours). Slow 
detachment of [18F]FBBA was observed at long times for NPs synthesized following 
strategy 3.  
Table 4.1 R.E. (%) for the NPs obtained by different strategies (radionuclide labelled to polymers P, 3P or 
encapsulated)  
18F-labelling 
strategy 
Radiolabelling 
efficiency (%) 
18F-P 5 
18F-3P  14 
18F-FBBA 10 
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4.3.2 Synthesis and Characterization of [125I]-labeled NPs 
 
Characterization of 125I-15F and 125I-REG 
Many different substances can be labeled by radioiodination. In most of studies with 
labeled molecules, it is necessary to measure very low concentrations of the substance 
under investigation, which in turn requires the preparation of high specific radioactivity 
labeled species. Two radioisotopes of iodine are widely available, 125I and 131I. 125I has a 
half-life of nearly 59 days and decays by electron capture to an excited state of 125Te, 
which decays immediately by gamma ray emission with a maximum energy of 35.5 keV. 
131I has a half-life of 8.02 days and decays 100% by electron emission, also resulting in the 
emission of gamma rays with a maximum energy of 364.5 keV (81.7%). As γ-emitters, both 
are useful for in vitro and ex vivo applications; the application of 125I in vivo is restricted 
due to the low energy of the gamma rays, which may lead to a significant attenuation, 
especially in large animals or humans. In the current study, 125I was the isotope of choice, 
due to its high specific radioactivity, reasonable price and adequacy for the purpose of the 
study.   15F-peptide was radiolabeled using a direct method in which labelling with 125I 
involved incorporation of 125I into tyrosine residues already present in the peptide 
(Scheme 4.9 A). This was done by treatment of the sample with Na125I in the presence of 
an oxidizing reagent to generate a source of electrophilic iodine. Iodination takes place at 
the ortho-positions to the hydroxyl group on tyrosine and mono- or di-substitution can 
occur. To prevent the potential degradation of the peptide in the presence of strong 
oxidizing agents, an insoluble derivative of the sodium salt of N-chloro-
benzenesulfonamide immobilized on nonporous, polystyrene beads (Iodo-Beads), was 
used as the oxidant. By using this reagent, the reaction was finalized by simply removing 
the beads from the reaction mixture. The radioiodination reaction kinetics was evaluated 
by determining the radiochemical incorporation at different times using HPLC equipped 
with a radiometric detector. As shown in Figure 4.7 A, the radioactivity ratio between free 
125I and 125I-15F was analyzed after 5, 10, 15 and 20 minutes of reaction and the highest 
15F radiolabelling efficiency was obtained after 15 minutes incubation (125I free/125I-
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15F=34:66). To ensure 125I-15F compound stability, the same collected and purified 
fraction was analyzed after 24 hours and as shown in Figure 4.7 B, no free 125I was 
detected proving stable incorporation of iodine into tyrosine residues. Radiolabelling of 
15F-functionalized-2P block co-polymer was also performed and the degree of 
radioisotope incorporation, analyzed by HPLC (Figure 4.7 C) was 125I / 125I-15F = 12/88.  
REG-peptide lacks accessible tyrosine residues, and hence an indirect radiolabelling 
method was used; with this purpose, free amines were reacted with N-succinimidyl-3-[4-
hydroxyphenyl] propionate (Bolton-Hunter) reagent, previously labelled with 125I. The 
presence of the N-hydroxysuccinimide (NHS) ester group reacts efficiently with primary 
amino groups of lysine at pH 7-9 to form stable amide bonds (Scheme 4.9 B). This 
condensation reaction was carried out in 15 minutes, leading to 77% labelling efficiency. 
The radiochemical stability of 125I-REG compound was analyzed after 24 hours by HPLC 
(Figure 4.8); no free 125I was detected. Radiolabelling of REG-functionalized-2P block co-
polymer was also performed following a parallel strategy with radiochemical conversion 
values close to 80%. 
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Scheme 4.9 Peptides radiolabelling with γ-emitting radioisotope 125I. (A) 15F-peptide radiolabeled by direct 
method incorporating 125I into tyrosine residues. (B) REG-peptide radiolabeled by indirect method involving 
conjugation of a preiodinated [125I] Bolton-Hunter reagent to primary amines of lysine to form stable amide 
bonds 
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Figure 4.7  Radioactive HPLC characterization of 125I-15F radiolabeling. (A) Reaction time study, 125I / 125I-15F 
ratio analyzed at different incubation times: (a) 5’ 78:22, (b) 10’ 73:27, (c) 15’ 34:66, (d) 20’ 53:47. (B) 125I-
15F stability test after 24 h; (C) 125I-15F-2P  
 
 
 
 
 
Figure 4.8  Radioactive HPLC characterization of 125I-REG radioactive detection HPLC. Top left: 125I / 125I-REG 
ratio analyzed at 15 minutes incubation time: 23 / 77; top right: 125I-REG stability test after 24h; bottom: 125I-
REG-2P 
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Characterization of 125I-15F-NPs and 125I-REG-NPs 
Activity of 125I-15F and 125I-REG-NPs, obtained by following the nanoprecipitation protocol 
describe in Chapter III and employing radiolabeled-peptide 2Ps, was measured before 
animal injections and ranged in 150-150 µCi. According to the measurements of particle 
size and zeta potential, the incorporation of the radiolabel did not result in statistically 
significant alteration of the physic-chemical properties of the resulting NPs; all the 
formulations exhibited average diameters and zeta-potential values within the required 
specifications (data not shown).  
 
 
4.3.3 In vivo and ex vivo experiments  
In vivo biodistribution in rats (PET-CT Imaging)   
In vivo biodistribution studies using PET imaging were carried out using the labelled NPs 
following strategy 2 (this is, using [18F]3P as labelled precursor). This decision was made 
based on radiochemical yields during particle preparation (see Table 4.1). The labelled 
precursors (namely [18F]FBBA and [18F]3P) were also investigated as controls. PET images 
(Figure 4.9) were acquired after NPs injections and quantified as shown in Figure 4.10. As 
expected, a pronounced lower uptake of the NPs in the liver than kidneys was 
ascertained. Renal excretion of the NPs became the favorite way when the surrounding 
PEG corona on the surface avoids rapid blood clearance through liver accumulation 18,19. 
Moreover, a marked renal uptake for 3P block co-polymer (Figure 4.11 A) was found 
during first 20 minutes, which confirms that although PEG presence, low molecular weight 
block co-polymers tended to renal excretion more than high molecular weight polymers11. 
Approximately constant uptake in organs in the first 2 hours (Figure 4.10) demonstrated 
no phagocytosis of the circulating NPs by the RES components of the liver. In this way, NPs 
blood circulation half-life can be increased and a prolonged blood circulation can result in 
a higher uptake by targeted tissue.  
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The stealth character of the NPs was confirmed by the higher liver uptake for the 18F-FBBA 
used as control, compared to NPs and 3P (Figure 4.11 B). This can be attribute to the lack 
of hydrophilic chains (PEG) in 18F-FBBA compound along with its high hydrophobicity. After 
liver accumulation, the excretion occurs across hepatocytes through the biliary production 
pathway. Hepatocytes have been shown to have phagocytic ability, although they are not 
as effective as Kupffer cells in capturing nanoparticles. Furumoto et al. 20 have found that 
polystyrene nanoparticles are taken up by both Kupffer cells and hepatocytes after 
intravenous administration. 
As was observed by many authors, nanoparticulate systems could produce hepatotoxicity 
because normally accumulate in liver11. This behavior can be attributed to the conjugate’s 
negative superficial charge, which favors the interaction with the RES. When the NPs are 
administered, a variety of plasma proteins (e.g. opsonins) bind to their surfaces. The 
conjugates can then be recognized by the macrophage cell surface and internalized, 
leading to a significant loss of NPs from circulation. Although negative superficial charge of 
the developed peptide-functionalized-NPs, opsonization and consequently liver 
accumulation was clearly avoided thanks to stealthy behaviour awarded to 
nanoparticulate system.  
 
 
 
 
 
 
 
 
 
Chapter IV – In Vivo evaluation of NPs pharmacokinetic properties 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Representative PET-CT image (coronal view) for the first frame acquired after an intravenously 
injection of (A)18F-FBBA, (B) 18F-PEGthiolAcid, (C) 18F-3P, (D) 18F-NPs(1), (E) 18F-NPs(2) and (F) schematic 
anatomical overview with localization of important organs.  
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Figure 4.10 Time-activity curves of the defined organs after intravenous injection of 18F-Peptide-
functionalized-NPs 
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Figure 4.11 Time activity curves of 18F-Peptide-NPs, 18F-FBBA and 18F-3P in (A) kidney and (B) liver   
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Ex vivo Pharmacokinetics and biodistribution in rats (Gamma-counter) 
In vivo biodistribution studies were performed by measuring the amount of radioactivity 
in blood samples and harvested organs at 2, 5 and 10 minutes post-injection. 
Exsanguination with perfusion after collection of the blood samples was applied to 
remove the contribution from the radioactivity present in the blood during determination 
of the radioactivity in the organs. As can be observed in Figure 4.12 A, 125I-15F-NPs 
distribution detected in liver and blood showed similar value to that of 125I-15F at each 
time point. The concentration of radioactivity in the blood decreased slowly, and a similar 
trend was found in the liver. Highest % ID/g of 125I-15F-NPs counted in the kidney was 
probably due to the low Mw of block co-polymers that tended to renal excretion more 
than high Mw polymers 11. The kidney is capable of rapidly removing molecules from the 
vascular compartment mostly as the injected forms and therefore, renal excretion 
represents a desirable pathway for NP removal with minimal catabolism. The higher levels 
of uptake in the kidney in comparison to the liver confirmed that the hepatobiliary system 
represents the primary route of excretion for NPs that do not undergo renal clearance 21.  
This confirmed the results of the biodistribution studies and proved the stealthy behaviour 
of NPs owing to external hydrophilic coating, which allowed avoid recognition by 
reticuloendothelial system and so rapid blood clearance through liver accumulation. 
Moreover, the liver is a major excretion route for larger NPs (>250 nm) 22. A significant 
uptake of 125I-15F in kidney was observed and according to previously reported findings by 
Vegt et al., radiolabeled peptides, including small fragments are excreted primarily via the 
kidneys because of accumulation mainly in the renal cortex 23. As expected, lower kidney 
uptake of 125I-15F-NPs in comparison with peptide alone was observed due to the 
presence of PEG-corona; the  insertion of 2- to 4-kDa PEG groups reduces indeed the renal 
uptake 18,19. Ex vivo biodistribution in brain revealed an uptake of 0.06 and 0.04 % ID/g for 
125I-15F and 125I-15F-NPs, respectively (Figure 4.12 B) with higher concentration in 
cerebellum with respect to the brain (Figure 4.12 C, D). To study the influx of radiolabeled 
peptides and NPs across the BBB, multiple-time regression analysis was used. The 
unidirectional influx rate (Ki) and clearance from blood (CL) for 125I-15F and 125I-15F-NPs 
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are shown in Table 4.2. The blood-to-brain entry data corresponding to 125I-labeled 
compounds are plotted in Figure 4.13 as expressed in eq XX. 15F and 15F-NPs showed 
linear, unidirectional uptake into brain with BBB transfer coefficients (Kin) of 4.52 ± 0.2 
and 1.5 ± 0.016 µl/g·min, respectively. Using 15F peptide, known to be able to cross the 
BBB, as positive control, we consider satisfactory the ~ 3 fold lower Kin of 125I-15F-NPs as 
compared to 125I-15F. Comparable values of clearance of 125I labeled compounds from 
blood were found (Figure 4.13) and consequently similar values of t1/2 were obtained 
(Table 4.2). Biodistribution of 125I-REG (Figure 4.14) showed lower values of % ID/g in 
kidney, brain and blood than 125I-15F along with an increased accumulation in the liver. 
Unlike 125I-15F, low levels in blood and high levels in liver suggested a rapid blood 
clearance through liver accumulation with the hepatobiliary system as predominant route 
of excretion of NPs. 125I-REG-NPs showed similar uptake levels to those found for 125I-15F-
NPs. Instead, the uptake in the brain was 6 fold lower (0.006 %ID/g). Multiple-time 
regression analysis (Figure 4.15) confirmed lower entrance of these in the brain with Ki 
values of 1.7±0.4 and 0.44 ± 0.1 for 125I-REG and 125I-REG-NPs, respectively. Moreover, in 
concordance with biodistribution data (high accumulation of REG in the liver and 
consequently low level in blood), low t1/2 (4 ± 0.9) and high clearance (12.6 ± 1.7) values 
were obtained (Table 4.2). Since REG peptide is able to cross BBB just like 15F and in the 
light of the low values of REG blood-to-brain data entry, we hypothesized an alteration of 
the transcytosis ability of the REG peptide due to the radionuclide insertion in the lysine 
residues. Indeed, the rigid β-hairpin structure and the area of the flexible region including 
residues R13, R19, K20 and K22, that are supposed interact with the LA domain of LDLR 
family, both contains lysine residues. Moreover, the alteration of lysine probably 
decreases hydrophylicity of the REG peptide, as reflected in a dramatically increased liver 
uptake and retention 18. 
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Table 4.2 Pharmacokinetic parameters of 125I labeled and peptides-functionalized NPs after iv administration 
in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
Ki  
(µl/g·min)  
t1/2 
(min) 
CL 
(ml/min) 
15F 4.52 ± 0,2 6 ± 0,42 2,1 ± 0,3 
15F-NPs 1.5 ± 0.016 4,35 ± 1,6 2,66 ± 0,21 
REG  1,7 ± 0,4 4 ± 0,9 12,6 ± 1,7 
REG-NPs 0,44 ± 0,1 10,6 ± 2,6 1,5 ± 0,55 
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Figure 4.12 125I-15F and 125I-15F-NPs biodistribution in mouse organs, harvested from each animal after 
exsanguination, washed with clean buffer saline and measured by scintillation counting to determinate total 
associated radioactivity. (A) kidney, liver, blood, plasma; (B) whole brain; (C) 125I-15F and (D) 125I-15F-NPs 
biodistribution in right, left brain and cerebellum 
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Figure 4.13 Multiple-time regression analysis for 15F and 15F-NPs. (Left) Blood-to-brain entry of 125I-15F and 
125I-15F-NPs into mouse brain after iv administration. The slope of the regression line between brain/serum 
ratio and exposure time is Ki (µl/g·min), the unidirectional influx rate reflecting blood-to-brain entry. (Right) 
Drug Clearance (DC) from blood of 125I-15F and 125I-15F-NPs; the half-time disappearance (t1/2) calculated 
from the slope, and the volume of distribution calculated from the intercept of the resulting line (Data are 
shown in Table 4.2, expressed as means ± SD) 
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Figure 4.14 125I-REG and 125I-REG-NPs biodistribution in mouse organs harvested from each animal after 
exsanguination, washed with clean buffer saline and measured by scintillation counting to determinate total 
associated radioactivity. (A) kidney, liver, blood, plasma; (B) whole brain; (C) 125I-REG and (D) 125I-REG-NPs 
biodistribution in right, left brain and cerebellum 
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Figure 4.15 Multiple-time regression analysis for REG and REG-NPs. (Left) Blood-to-brain entry of 125I-REG 
and 125I-REG-NPs into mouse brain after iv administration. The slope of the regression line between 
brain/serum ratio and exposure time is Ki (µl/g·min), the unidirectional influx rate reflecting blood-to-brain 
entry. (Right) Drug Clearance (DC) from blood of 125I-REG and 125I-REG-NPs; the half-time disappearance 
(t1/2) calculated from the slope, and the volume of distribution calculated from the intercept of the 
resulting line (Data are shown in Table 4.2, expressed as means ± SD) 
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4.4 Concluding remarks 
This chapter describes and discusses various approaches and methods for the 
radiolabelling of NPs for PET-CT imaging and gamma counting, respectively, using 
radionuclide positron and gamma emitters. These techniques represent an ideal tool for 
investigations of pharmacological profiles of the drug delivery system. 
 
Since new approaches need to be explored for investigate the in vivo fate of the NPs, this 
chapter give rise to a new strategy for conjugation of polymeric NPs with 18F for 
non-invasive imaging by means of PET. Otherwise, NPs radiolabelling through peptide 
conjugation, was also performed with 125I because its high specific radioactivity allows to 
measure very low concentrations of the substance under investigation. 
 
In vivo and ex vivo pharmacokinetics and biodistribution studies in rats performed 
injecting by iv bolus, radiolabeled NPs, have allowed a semi-quantitative measurement of 
the organ biodistribution of the system in mice. Both NPs formulations, functionalized 
with 15F and REG, showed stability in biological environments with no accumulation in 
liver and low accumulation in kidney. This stealthy behaviour of NPs is due to external 
hydrophilic coating that allows avoid recognition by reticuloendothelial system and so 
rapid blood clearance through liver accumulation. In this way, NPs blood circulation 
half-life was increased and organs uptake 2 hours after injection was found slightly lower 
than after 20 minutes. This prolonged blood circulation is a promising result because it can 
result in a higher uptake by targeted tissue. 
 
Additionally, a special attention was given to quantitatively brain uptake of NPs by using a 
theoretical model of blood-brain exchange. The pharmacokinetic study was carried out to 
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study the influx of the radiolabeled and peptides functionalized NPs across the BBB after 
injection. Multiple-time regression analysis was adapted to assess the fraction of the 
administered dose that is distributed within the BBB complex or is excreted from the 
body, based on a two-compartment mathematical model. 15F-NPs showed satisfactory 
values of penetration into brain tissues as compared to peptides known to be efficiently 
transported across the BBB. Along with unidirectional influx rate, comparable values of 
clearance from blood and consequently similar values of t1/2 were found. 
 
On the other hand, biodistribution of REG-NPs in liver and kidney showed similar uptake 
levels to those found for 15F-NPs but on the contrary, the uptake in the brain was rather 
lower. In the light of the low values of REG-NPs blood-to-brain data entry obtained by in 
vivo and ex vivo studies, we hypothesized an alteration of the transcytosis ability of the 
REG peptide due to the radionuclide insertion in the lysine residues.  
 
The promising results obtained evaluating the potential of the peptide functionalized NPs 
as brain targeting drug delivery system, along with the possibility to select the target by 
functionalizing NPs with any family of peptides, suggested that the nanoparticulate 
system might have great potential for glioma therapy in clinical applications. Next chapter 
(Chapter V) presents the impact that the developed nano-platform had in terms of 
contribution and innovation in our research group. The outcome was the foundation of a 
company, Sagetis Biotech, devotes to developing innovative drug delivery technologies 
and with the aim to improve our system and to explore new possible applications for the 
unmet medical needs. 
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This work gives rise to a new system capable to solve some of the major bottlenecks found 
in polymeric nanoparticulate systems designed for brain targeting drug delivery.  
 
The novel drug delivery platform described in this thesis represents an efficient term for 
comparison with the mainly used nanoparticles system based in PLA-PLGA. Although NPs 
are composed by two or more different polymers (P, 2P or 3P), the preparation method is 
simplified and it is carried out in only one step and without emulsifier. 
The polymer used is new and its special characteristics and innovative character lead to a 
considerable improvement in drug loading and in controlled release.  
The considerable increase of PTX encapsulated into nanocarriers makes the system 
suitable for intravenous administration since no very concentrated solutions can be 
injected. Specifically, the high drug contents achieved are an absolute novelty for block 
polyester-based nanoparticles. Similar values of PTX cargo are accomplished by other 
authors, employing polyester block copolymers, but for micellar carriers [1]. The use of 
drug-loaded polymeric micelles is limited by their low stability in aqueous solution; 
stability that becomes even lower when the drug loading content increases [2]. The poor 
stability also was remarked in blood as well as insufficient binding and uptake by cells [3]. 
The inherent instability of micelles, along with their rapid clearance from circulation 
remains a significant challenge. 
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For many polyester-based NPs such as for polymeric micelles, very fast complete release 
or biphasic profile characterized by burst release, is frequently observed [4, 5, 6]. The release 
behaviour of PTX from the NPs developed in this work, exhibits an approximately 
first-order profile, without initial burst, and characterized by a slow and constant release. 
The improved release profile, along with the possibility to control the release rate by 
setting the hydrophobic character of the NPs, represents an important advance in the 
polyester-based NPs systems field.  
 
The flexibility in design of nanoparticle delivery system offers an opportunity to engineer 
the components based on the desired application. As a result, the surface can be modified 
with PEG allowing to reduce nonspecific interactions with proteins, resulting in increased 
blood circulation times. 
Moreover, depending on the target, NPs can be easily functionalized with the appropriate 
family of peptide to enhance cellular uptake and accumulation in tumor tissue through 
binding and endocytosis.  
 
In this scenario, this whole thesis has sought to demonstrate that peptide functionalized 
and PTX loaded NPs are promising candidates for glioma therapy in clinical applications, 
given their loading capacity and efficacious targeting, which improve therapeutic index 
and avoid the adverse effect of an uncontrolled release. 
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The degree of contribution and innovation of this work paved the way to the birth of a 
company, Sagetis Biotech, devotes to developing innovative drug delivery technologies. 
Starting from the results here obtained, Sagetis Biotech put a great deal of effort into this 
project to improve the system with the aim to lead up the polymeric drug delivery 
platform to the clinical trials.  
 
First requirement, in view of the scaling up the process, consisted in plentiful raw 
materials to be employed for production in industry. The fabrication methods needed to 
be modified and adapted to the large-scale production. To perform the scaling up, Sagetis 
Biotech decided to synthetize polymers without microwave to obtain most purified 
starting materials. Thanks to key partners for animal testing, a slightly modified 
nanoparticulate system, here developed, was further in vivo characterized before to start 
preclinical research. Pharmacodynamics, pharmacokinetics, ADME and toxicity studies 
through animal testing are currently in progress.  
 
Thanks to the flexibility in the design, the technology here developed has proved to be 
similarly efficient in other fields different from brain delivery.  The same base 
components, engineered as required, have been employed for new applications with the 
aim to satisfy the unmet medical needs. Among them, a functionalized PDMS surface used 
as antibacterial coating and able to avoid biofilm formation was customized by modifying 
the NPs here developed. In view of its use as a tracheal prosthesis, the PDMS surface was 
functionalized with the drug loading nanoparticulate system to treat scarring tissue or 
granuloma formation. This promising modification consists in modifying P block 
co-polymer to obtain superficially aminated NPs that can be easily immobilized on a 
previously functionalized PDMS substrate. 
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The wide range of possible applications is due to the flexibility in the design of the 
developed nanoparticulate system.  Potentially, the same technology could be extended 
to many fields and with different purposes. 
A further application of the discussed nano-platform concerns a new mucus-barrier 
penetrating system that allows NPs to be slippery into the mucus barrier avoiding rapid 
mucus clearance. Superficially thiolated and PEGylated NPs opens opportunities for the 
system to be used for targeted drug delivery in mucus-coated areas.  
 
In addition to the impact so considerable as to lead to Sagetis Biotech foundation, the 
proposals of this thesis demonstrate a wide prospective of applications that can be 
on-demand and easily customized, depending only on the desired application. 
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A custom-tailored, polymeric drug delivery system for the anticancer drug PTX, intended 
to be intravenously administered, capable of improving the therapeutic index of the drug 
and devoid of the adverse effects of an uncontrolled release has been developed, 
optimized and characterized. 
 
 A novel block co-polymer (P) has been successfully synthetized to obtain via 
nanoprecipitation or emulsification-solvent evaporation method, a very 
monodisperse PTX-NPs population. A clear correlation between NPs characteristics 
and formulation parameters has been found in order to entirely customize NPs in 
terms of size, zeta-potential, drug loading and release profile.  
 
 PTX-loaded NPs have been proved to be spherical in shape at the desired size and 
polydispersity ranges and with a surrounding PEG corona on the surface. Due to 
the strong lipophilic interactions of the drug with the hydrophobic inner region of 
NPs, PTX content has been considerably increased and its amorphous physical 
state has been confirmed by DSC.  
 
 In vitro experiments have demonstrated that NPs release PTX with an 
approximately first-order profile and without initial burst. The total cargo of loaded 
PTX has been shown to change the hydrophobic character of the NPs, allowing to 
set the release profile in a modulated and controlled way. Biocompatibility and in 
vitro anti-tumoral activity against a human primary glioblastoma cell line have 
been assessed. It has been also demonstrated that the cytotoxicity against tumoral 
cells is time- and drug concentration-dependent.  
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PTX loaded NPs have been satisfactorily functionalized with an appropriate family of 
peptides for dual-targeting purposes to shuttle drug from across the BBB, and then target 
glioma cells. 
 
 A novel biodegradable block co-polymer (2P) has been successfully synthetized and 
in combination with P, has been employed to produce in one step and via modified 
nanoprecipitacion emulsifier-free method, a very monodisperse peptide 
functionalized and PTX loaded NPs population.  High drug loading and in vitro PTX 
controlled release have been also corroborated. 
 
 The functionalization of NPs has been carried out employing a family of peptides 
known to be efficiently transported across BBB by a membrane receptor (LRP) that 
also is over-expressed on human glioma cells. Crosslinking via sulfhydryl groups has 
been assessed as method for coupling NPs and peptides.  
 
 The developed strategy has proved to induce cellular uptake by active transport 
both in endothelial cells and glioma cells.  
 
 In vitro co-localization experiments performed on human primary glioblastoma 
cells suggest that the mechanism used by the peptide-functionalized NPs is LRP-1 
dependent. 
 
 The dual-targeting effect has been optimized and an enhanced in vitro anti-
tumoral activity against glioma cells, compared with non-functionalized-PTX-NPs, 
has been demonstrated. 
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 Transcytosis experiments using an in vitro BBB model, have demonstrated that a 
significant increased transendothelial transport ratio of PTX is achieved when the 
drug is loaded in the peptide functionalized NPs. 
 
The relevant in vivo pharmacokinetics, biological profile and biodistribution properties of 
the developed nanocarriers have been assessed.  
 
 Various novel strategies and methods including the synthesis and purification of 
the optimized NPs, labeled with radionuclide gamma or positron emitters to 
perform PET-CT and gamma counting studies, respectively, have been explored.  
 
 In vivo and ex vivo characterizations have been carried out through a 
semi-quantitative measurement of the organ biodistribution. Peptide 
functionalized NPs can be considered stable in biological environments with a 
pronounced lower uptake in the liver compared to kidneys. NPs show a stealthy 
behavior and the approximately constant uptake in major organs demonstrates no 
phagocytosis of the circulating NPs by the RES components of the liver, suggesting 
that rapid blood clearance through liver accumulation has been avoided. 
 
 In order to evaluate the potential of peptide functionalized NPs as a brain targeted 
drug delivery system, special attention has been given to brain uptake by using a 
theoretical model of blood-brain exchange, with the aim to study the influx of the 
NPs across the BBB after iv injection. Multiple-time regression analysis, based on a 
two-compartment mathematical model has evidenced that developed NPs enter 
the brain with satisfactory levels of penetration when compared to peptides 
known to be efficiently transported across the BBB. Along with the unidirectional 
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influx rate, comparable values of clearance from blood and consequently similar 
values of t1/2 have been found. Also, it has been ascertained that when the 
radionuclide insertion takes place in the peptide regions that are supposed to 
interact with the BBB receptors, low values of blood-to-brain entry are achieved, 
hypothesizing an alteration of the transcytosis ability of the labeled peptide.  
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